

Appendix

Data from Phase 2 and Phase 3 Expanded Safety and Efficacy Clinical Trials

The presented data are referred to in Chapter 16, “Socioeconomic and Behavioral Factors Influencing Choice, Adherence and Success of Microbicide Formulations,” and were compiled by its authors.

Table A.1 Cohorts and summary adherence data from Phase 2 and 3 expanded safety and efficacy clinical trials of microbicide candidates conducted between 1986 and 2013

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
N-9 sponge (1986)	Design and regimen: RCT, cross-over, OL: N-9 sponge vs. control (nothing), sponge before 1st partner; after 3 partners, remove 6 h ALP. Intended outcome: NG/CT prevention. Follow-up (retention rate): 12 w, weekly FU, 6 w per arm. Cohort (number, description): 312 FSW, recruited from 4 massage parlors. Sites: 1 (Bangkok, Thailand). Baseline characteristics: A: μ 23 y; M: 40–42% single, 32–33% divorced; E: >50%, <7 y; NP: >50%, 5–10 PPW; FP: >95% HC (87–93% OC)	Sponge users partially protected against NG and CT, but increased risk of candidiasis	Not available (authors claim compliance was high due to unscheduled compliance checks; no specifics provided re-compliance rates or checks)	[1]

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
N-9 gel (1984–1986)	Design and regimen: Phase 3, RCT: N9 gel vs. PL (Koromex Crystal Clear Gel), pa. Intended outcome: NG/CT prevention [no info on SS calculation]. Follow-up (retention rate): 6 m, monthly FU (78% RET). Cohort (number, description): 818 ♀, 19–29 y, attending STD clinic. Sites: 1 (Birmingham, AL, USA). Baseline characteristics: A: μ 23 y; M: 18%; NP: μ 1 PPM during trial; CF: μ 5 APW during trial; FP: 75% OC	N-9 reduced NG/CT risk; stronger protective effect for ♀ using gel for majority of acts	Not available	[2]
N-9 film (1990)	Design and regimen: RCT, OL, partially blinded: N9 film vs. PL (lubricant), pa (clinicians blinded). Intended outcome: NG/CT prevention [no info on SS calculation]. Follow-up (retention rate): μ 3 w (1–9 w) FU (75% RET). Cohort (number, description): 343 ♀; recruited from 6 massage parlors where study procedures took place. Sites: 1 (Bangkok, Thailand). Baseline characteristics: A: 43–47% <20 y; M: 65–67% unmarried; E: 79–80% primary; NP: 44–46%, 8–14/w; Other: 64–66% ever had STD	N-9 reduced NG/CT rates by 25% overall and 40% in ♀ >75% compliant	24–32% ♀ compliant for 0–50% of acts; 20–29% compliant for 51–75% of acts; 47–48% compliant for 76–100% of acts	[3]

N-9 sponge (1987–1990)	Design and regimen: Phase 3, RCT, OL: N-9 sponge v PL (suppository or gel), sponge before 1st partner; after 2–3 partners, remove 6 h ALP (PL qd). Intended outcome: 37 endpoints → 75% HIV risk reduction. Follow-up (retention rate): μ 9 m [1–46 m] (84% RET). Cohort (number, description): 138 FSW, 18 y+, enrolled through attendance at STD clinics. Sites: 1 (Nairobi, Kenya); estimated HIV incidence was 20%/y. Baseline characteristics: A: μ 29–30 y; CF: μ 42–56 APW; C: 51–54% of partners; FP: 22–28% OC	Study terminated early per DSMC recommendation due to AE	μ compliance: 81%, sponge, 90%, PL; 90% (sponge) and 95% (PL) users $\geq$ 50% compliant, 73% (sponge) and 90% (PL) users $\geq$ 75% compliant	[4]
N-9 suppository (1989–1990)	Design and regimen: Observational; Single arm, OL: N-9 + condom, pa. Intended outcome: HIV prevention [no info on SS calculation]. Follow-up (retention rate): 1 y, monthly FU, μ 8.1 m (92% RET). Cohort (number, description): 273 FSW, 18 y+, recruited from bars. Sites: 1 (Yaounde, Cameroon). Baseline characteristics: A: 73% $\leq$ 29 y; M: >90% single; E: 49% primary, 93% could read; B: 84% $\geq$ 1; NP: 64% $\geq$ 4–7 PPW; C: 58% never use; FP: none>15%	First epidemiological evidence that N-9 spermicides can reduce incidence of HIV infection (RCT needed)	20% ♀ reported no unprotected sex (neither N-9 or condom); 50% reported N-9 use >67% of acts; 50% reported condom use >63% of acts	[5] (see also [6])
N-9 suppository (1989–1990)	Design and regimen: Observational; Single arm, OL: N-9 + condom, pa. Intended outcome: NG prevention [no info on SS calculation]; secondary analysis from [5]. Follow-up (retention rate): 1 y, monthly FU, μ 8.1 m (92% RET). Cohort (number,	N-9 affords significant protection when condoms not used	μ 40% acts, N-9 + condom; μ 22% acts, N-9 alone; μ 25% acts, condom alone; μ 12% acts, neither; 8% ♀	[7]

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	description): 273 FSW, 18 y+, recruited from bars. Sites : 1 (Yaounde, Cameroon). Baseline characteristics : A: 73% ≤29 y; M: >90% single; E: 49% primary, 93% could read; B: 84% ≥1; NP: 64% ≥ 4–7 PPW; C: 58% never use; FP: none >15%		reported N-9 + condom >75% acts	
N-9 film (1995–1996)	Design and regimen : Phase 3, RCT: N-9 film vs. PL, pa. Intended outcome : 88 endpoints → 50% HIV risk reduction. Follow-up (retention rate) : μ 14 m FU; 73% ≥1 y (82% RET). Cohort (number, description) : 1292 FSW, 18–45 y, μ ≥4 PPM. Sites : 2 (Yaoundé and Douala, Cameroon); estimated HIV incidence was 10%/y. Baseline characteristics : A: μ 26 y; M: 95–97% unmarried; E: 99% able to read; B: μ 1.4 living children; AI: 16–17% (ever); C: 48–49% with last client; FP: 86–87% none	N-9 not effective for prevention of NG, CT, HIV	Film + condom: 83–86% AWC, 63–69% AWP; film: 3–4% AWC, 15–18% AWP; condom only: 10–13% acts, AWP	[8]
N-9 gel [Advantage 24 [®]] (1996–1998)	Design and regimen : Phase 3, RCT: N9 vs. PL (polycarbophil and carbomer base for N-9), 1 qd; re-apply within 24 h if douched/cleaned the vagina. Intended outcome : NG/CT prevention [no info on SS calculation]. Follow-up (retention rate) : median 50 w FU; (at 12 m: 61% [PL] and 69% [N9] RET). Cohort (number, description) : 278 FSW, 18 y+, enrolled through	Significantly higher incidence of NG in N-9 group; no differences for other STDs (not powered for determining effect for syphilis or HIV)	Median compliance: 78% [0–100%]; 100% compliant; 34%; <25% compliant: 13%	[9]

	STD clinic attendance. Sites: 1 (Mombasa, Kenya); no information on incidence. Baseline characteristics: A: μ 28 y; M: 52% ever married; E: μ 7 y [0–15]; B: μ 1 live birth [0–8]; NP: μ 1 PPW [1–5]; CF: μ 2 APW [0–7]; C: 68–71% consistent (ND); FP: 44–55% none			
N-9 gel [Conceptrol®] (1998–2000)	Design and regimen: Phase 3, RCT, OL: N9 + condom vs. condom only; pa (≤ 1 h). Intended outcome: 90 endpoints $\rightarrow$ 90% STD (GC/ CT) risk reduction. Follow- up (retention rate): 6 m FU (93% RET). Cohort (number, description): 1251 ♀; 18 y+, being treated for/with STD symptoms (excluding FSW). Sites: 20 (10 community clinics and 10 pharmacies in Younde, Cameroon). Baseline characteristics: A: μ 25 y; M: 65% unmarried/NLT; E: high education attainment (ND); B: 53–54% none; NP: μ 1 (last 30 d); CF: μ 3 (last 7 d); CLS: 63–65% did not use; FP: <5%	N-9 safe but not effective; lost to FU not differential by group; more acts with no protection in gel + condom group vs. condom only	Gel: 76% of acts (63% with gel plus condom); condoms: 81%	[10]
N-9 vaginal gel (1996–2000)	Design and regimen: Phase 3 [design was Phase 2 B/3 but only Phase 3 data are included], RCT: N9 vs. PL (Replens® lubricant gel), pa (≤ 1 h). Intended outcome: 100 endpoints $\rightarrow$ 50% HIV risk reduction. Follow-up (retention rate): 48 w FU (71% RET at 24 w, 68% RET at 48 w). Cohort (number, description): 892 FSW, 18 y+ (16 y+ in South Africa), enrolled in STD clinics,	Did not show protective effect of N-9. Possible increased risk of HIV (stop further studies of N-9 as microbicide)	52–53 % ♀ reported gel $\geq 95\%$ AWC; 31–34% reported gel = 100% AWC. Overall—79–81% AWC, 68–72% AWP; Cotonou, Benin—86–88% AWC, 57–65% AWP; Abidjan, Côte d'Ivoire— 76–79% AWC, 29–36% AWP;	[11]

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	sex-worker clinics, or truck stops (Durban). Sites: 4 (Cotonou, Benin [<i>n</i> = 259], Abidjan, Côte d'Ivoire [<i>n</i> = 188], Durban, South Africa [192], Hat Yai, Thailand [194]); estimated HIV incidence was 5%/y. Baseline characteristics: [Total] A: median 26 y; E: median 6 y; NP: median 3 clients/d; AI: 14% ever, mean 2 APW; C: ≈66% >50% clients, less than 15% >50% partners; FP: 17% OC, 14% injectable HC, 4% TL, 22% other. [Cotonou, Benin] A: 28 y; E: 7 y; NP: 3 clients/d; AI: 8% ever; C: 54% clients, 5% partners; FP: 10.5% hormonal, 50% other; [Abidjan, Côte d'Ivoire] A: 25 y; E: 9 y; NP: 4 clients/d; AI: 5% ever; C: 98% clients, 11% partners; FP: 7% OC, 32% other; [Durban, South Africa] A: 24 y; E: 6 y; NP: 4 clients/d; AI: 41%, 3×/w; C: 17% clients, 7% partners; FP: 14% OC, 44% injectable HC, 7% other; [Hat Yai, Thailand] A: 26 y; E: 6 y; NP: 2 clients/d; AI: 4.4%, 1×/w; C: 100% clients, 14% partners; FP: 28% OC, 15% TL, 12% injectable HC		Durban, South Africa—76–84% AWC, 80–85% AWP; Hat Yai, Thailand—60–66% AWC; 29–36% AWP	
Carraguard vaginal gel (1999–2000)	Design and regimen: Phase 2, RCT: Carraguard vs. PL (methylcellulose), qod plus pa (≤1 h). Intended outcome: Detect 1.6× increase in genital findings with epithelial	Carraguard found safe and acceptable for use 3×/w for up to 1 y	87–96% ♀ returned at least 3 applicators/w (minimum adherence); μ 4 applicators/w	[12]

	disruption. Follow-up (retention rate): 1 y FU (90% RET). Cohort (number, description): 165 ♀, 18 y+, recruited from FP and general health clinics. Sites: 1 (Chiang Rai, Thailand). Baseline characteristics: A: μ 31–32 y; M: >95%; E: μ 6.4–7.2 y; B: 95% $\geq$1 live birth; NP: 2.4% >1; CF: μ 2.4–2.1 APW; AI: 0 (year before screening); C: 1–5% consistent (ND), 29–39% inconsistent (ND); FP: 92% using 2/3 HC		(counting/ weighing used applicators). 84–91% sex acts with gel (SELF)	
Dextrin sulfate (DS) vaginal gel (2001)	Design and regimen: Expanded safety, 4-arm RCT: DS bid, PL (lactic acid, carbopol, sodium hydroxide, and purified water—base for DS gel) bid, DS pa, and observation only. Participants had to fill applicators prior to each application. Intended outcome: Safety. Follow-up (retention rate): 4 w FU (96% RET). Cohort (number, description): 109 ♀, 18–45 y (sex $\geq$2$\times$/w), recruited from post-natal clinics near Nsambya Hospital. Sites: 1 (Kampala, Uganda). Baseline characteristics: A: μ 28 y; E: 55% completed primary; CF: 95% reported 2–3 APW	Results show satisfactory safety and acceptability profile of DS gel	89% of participants reported twice daily use during 28 d FU	[13]
Carraguard vaginal gel (1999–2002)	Design and regimen: Phase 2, RCT: Carraguard vs. PL, qod, plus pa ($\leq$1 h). Intended outcome: Safety (powered to detect difference in rates of genital findings). Follow-up (retention rate): 6–12 m FU (77% RET). Cohort (number, description): 400 healthy, HIV negative ♀, 18 y+,	Safe, acceptable	Minimum adherence ($\geq$ 9 applications/m) = 85–97%. Gel use >80% sex acts (SELF)	[14]

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	recruited from FP and general health clinics. Sites: 2 (Ga-Rankuwa, Gauteng and Gugulethu, Western Cape, South Africa). Baseline characteristics: A: μ 28 y [18–55]; M: 59% steady partner (NLT), 13–14% no steady partner; E: 89% $\geq$ secondary; B: 31% = 0, 34% = 1; NP: 7.5% had other partners; CF: not asked; FP: 54% injectable HC, 15–16% OC; 18–19% none			
Carraguard vaginal gel (2001–2002)	Design and regimen: Phase 1/2, RCT: Carraguard vs. PL (methylcellulose), pa (≤ 1 h); condom if perceived risk of STD/HIV. Intended outcome: Safety (powered to detect difference in genital findings). Follow-up (retention rate): 6 m FU (95% RET). Cohort (number, description): 55 low risk, monogamous couples, 18 y+. Sites: 1 (Chiang Rai, Thailand). Baseline characteristics: A: μ ♀ 31–34 y, μ ♂ 35–36 y; M: 100%; E: μ ♀ 5–7 y [0–16], ♂ 6–7 y [0–14], B: μ 1.5–1.8 live births; NP: 1 (eligibility criteria); CF: 1.8–2 APW; C: 79–93% never, 7–21% inconsistent (ND); FP: 32–48% OC, 26–39% TL, 4–11% none	Safe for ♀ and ♂; μ 91% adherence acceptable	[sex acts with gel only, no condom] based on count/ weighing used applicators and ♀ SELF	[15]
Ortho® All-Flex® Arcing Spring Diaphragm (2003–2006)	Design and regimen: Phase 3, RCT: diaphragm + Replens® lubricant gel + condoms vs. condoms only; insert diaphragm any time before	Diaphragm had no protective benefit against HIV in addition to condoms and	Diaphragm ALS: 73% of the time (SELF)	[16]

	coitus and leave in place for 6 h after sex; condom pa; insert additional lubricant pa. Intended outcome: 5000 ♀ = 90% power → 33% HIV reduced risk. Follow-up (retention rate): μ 21 m [12–24] FU (93% RET). Cohort (number, description): 4948 ♀, 18–49 y, sex μ 4/m, recruited from community-based organizations, FP, well-baby and general health clinics; print ads, radio. Sites: 3 (Durban and Johannesburg, South Africa and Harare, Zimbabwe); estimated HIV incidence was 3.5–5%/y. Baseline characteristics: A: 38% $\leq$24 y, 39% 25–34 y; M: 59%; E: 43% $\geq$high school; NP: μ 2 [1–30] lifetime; CF: 35% $>3\times/w$; C: 68% last sex act; FP: 25% injectable HC, 36% OC, 20% barrier method, 13% none	comprehensive HIV prevention program	
SAVVY® (C31 G) vaginal gel (2004–2006)	Design and regimen: Phase 3, RCT: SAVVY® vs. PL (HEC), pa ($\leq$1 h). Intended outcome: 66 endpoints → 50% HIV risk reduction. Follow-up (retention rate): 12 m FU (85% RET); trial stopped early. Cohort (number, description): 2142 ♀ ($\geq$3 APW, $\geq$2 PPM last 3 m), 18–35 y, not FSW per se (most exchanged sex for cash), recruited from markets, bars, hotels. Sites: 2 (Accra and Kumasi, Ghana); estimated HIV incidence was 5%/y. Baseline characteristics: A: μ 23 y (SD 3.6); M: 88% unmarried/NLT;	Stopped early due to lower than anticipated HIV incidence	Percentage usage [17] in all sex acts in 7 d prior to visits (SELF): gel 75–77%, gel + condoms 70–72%, gel only 5%. Percentage usage of gel in all sex acts without condom was 43–47% (SELF)

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	E: 76–77% ≤9 y; B: 73% ever pregnant, μ 2.1; NP: μ 6 PPM (last 30 days); CF: μ 9–10 APW; C: 40% CLS; FP: 46–48% condom, 37–40% none			
SAVVY® (C31 G) vaginal gel (2004–2006)	Design and regimen: Phase 3, RCT: SAVVY vs. PL (HEC gel), pa (≤ 1 h). Intended outcome: 66 endpoints → 50% HIV risk reduction. Follow-up (retention rate): 12 m FU (77% RET); trial stopped early. Cohort (number, description): 2153 ♀ (≥ 2 APW, ≥ 1 partner last 3 m) 18–35 y; from markets, bars, hostels, military barracks, colleges. Sites: 2 (Lagos and Ibadan, Nigeria); estimated HIV incidence was 5%/y. Baseline characteristics: A: μ 24 y (SD 3.7–3.8); M: 86% not married/NLT; E: 70–72% ≥ 9 y; B: 75% ever pregnant, μ 1.4; NP: μ 13 PPM, last month; CF: μ 9.5–9.6 APW; FP: 69–72% condom, <10% none	Stopped early due to lower than anticipated HIV incidence	Percentage usage in all sex acts in 7 d prior to visits (SELF): gel μ 78–79%, condom μ 87%, gel + condom 69–70%, gel only 4–5%. Gel used 62% of all sex acts (SELF)	[18]
Cellulose sulfate gel plus diaphragm (2004–2005)	Design and regimen: Phase 2, RCT (3-arm, partially blinded): diaphragm + CS gel vs. diaphragm + PL (K-Y® jelly) vs. CS gel alone, pa; apply gel in dome of diaphragm prior insertion, plus gel within 1 h BS (keep diaphragm 6–24 h); gel only: insert ≤ 1 h BS. Intended outcome: Safety and adherence. Follow-up (retention rate): 6 m FU (89% RET). Cohort (number,	High acceptability but only moderate adherence reported; consistent condom use and consistent product use were highly correlated	87% ♀ ever used diaphragm and 96% ever used gel; 71% ♀ reported product LS: 66% diaphragm + gel and 80% gel only; 59% ♀ reported using product every act	[19]

	description): 119 ♀, 18–49 y, recruited from reproductive health/FP clinics. Sites: 1 (Harare, Zimbabwe). Baseline characteristics: A: μ 29 y; M: 97%; E: μ 10.3 y; C: 85% ever used, 38% LS; CF: median 5 APW [2–11]; FP: 72% OC, 26% injectable HC		
ACIDFORM vaginal gel plus diaphragm (2004–2005)	Design and regimen: Phase 2, RCT: ACIDFORM gel + diaphragm vs. PL (K-Y® jelly) + diaphragm, insert 1 dose gel after placement of diaphragm, group new dose with each sex act, keep diaphragm in 6–24 h. Intended outcome: Safety and feasibility. Follow-up (retention rate): 6 m FU (82% RET). Cohort (number, description): 120 HIV-sexually-active ♀, 18–48 y, recruited from FP/community clinics and others. Sites: 1 (Yeoville, Johannesburg, South Africa). Baseline characteristics: A: μ 29.4 y; M: 59% living with partner; E: μ 11 y; B: 86% ever pregnant; FP: 50% OC, 44% injectable HC	Trend toward more safety events in ACIDFORM gel group	Proper use reported for 94–98% of sex acts; 26 ♀ reported incorrect/inconsistent use at some point during study [20]
Praneem polyherbal vaginal tablet (2004–2006)	Design and regimen: Phase 2, RCT: Praneem gel vs. PL, pa ($\leq 1/2$ h). Intended outcome: Safety and acceptability. Follow-up (retention rate): 6 m FU (95% RET). Cohort (number, description): 100 sexually-active monogamous ♀, 18–45 y. Sites: 1 (Pune, India). Baseline characteristics: A: μ 30–31 y; M: 98–100%; E: 74–78% >4th grade; C: 92–96% inconsistent (ND)/never	Praneem found safe for coital use up to 6 m among low-risk ♀; ♀ reporting that gel interrupted sex were less likely to be adherent.	70.5% reported [21] 100% adherence; (see also 29.5% reported <100% adherence [22])

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
Invisible Condom [®] vaginal gel (not published)	Design and regimen: Phase 2, RCT: PL (HEC gel) vs. polymer alone vs. polymer plus SLS (sodium lauryl sulfate), bid, ≤4 sex acts per each 14 days gel application, apply gel ≤1 h of planned sexual intercourse. Intended outcome: powered to detect AE rates >13%. Follow-up (retention rate): 8 w FU (77% RET). Cohort (number, description): 194 ♀, 18–49 y. Sites: 1 (Yaounde, Cameroon). Baseline characteristics: A: μ 30 y	Invisible Condom [®] formulations and applicator were well-tolerated when applied intravaginally bid for 2 w	70–86% compliance; however, only 20% of gel applications coincided with sex	[23]
Cellulose sulfate vaginal gel (2005–2007)	Design and regimen: Phase 3, RCT: CS gel vs. PL (HEC gel), pa (≤1 h). Intended outcome: 66 endpoints → 50% risk reduction [no info on SS calculation]. Follow-up (retention rate): 12 m FU (88% RET). Cohort (number, description): 1393 ♀, 18 y+, FSW at some sites (≥3 PPM, ≥3 APW), recruited via FSW peer education net-works, clinics. Sites: 5 (Cotonou, Benin [<i>n</i> = 227], Kampala, Uganda [<i>n</i> = 303], Durban, South Africa [<i>n</i> = 592], Chennai, India [<i>n</i> = 253], Bagalkot, India [<i>n</i> = 23]); estimated HIV incidence was 4%/y. Baseline characteristics: A: median 29 y; M: 22.9%; E: median 8 y; NP: median 10 CPM (last 3 m); CF: median 4 APW (last 7 d); AI: 3.7%	No protective effect shown. Interim results suggested possible increase in HIV risk (study stopped early)	Gel used in 87% of all sex acts of previous 7 d (SELF); condoms used in ≈95% of sex all acts; gel used in 45% of sex acts without condom. [Cotonou, Benin] gel use: 63% AWMP, 94% AWOP (last 7 d); [Kampala, Uganda] gel use: 60% AWMP, 85% AWOP (last 7 d); [Durban, South Africa] gel use: 91% AWMP, 95% AWOP (last 7 d); [Chennai, India] gel use: 38% AWMP, 91% AWOP (last 7 d);	[24]

	(last 1 m before screening); CLS: 61%; FP: 44.4% (HC, IUD, TL). [Cotonou, Benin] A: median 28 y; M: 0%; E: median 6 y; NP: median 125 CPM (3–840); CF: median 14 APW last 7 d; CLS: 72%; FP: 8 %; [Kampala, Uganda] A: median 25 y (18–48); M: 5%; E: median 7 y; NP: 180 CPM (3–1580); CF: median 21 (3–210); CLS: 87%; FP: 37%; [Durban, South Africa] A: median 31 y; M: 10%; E: median 10 y; NP: median 3 CPM (3–12); CF: median 4 (3–70); CLS: 38%; FP: 46%; [Chennai, India] A: median 35 y; M: 88% (41% NLT); E: median 7 y; NP: median 30 CPM (3–720); CF: median 5 (3–60); CLS: 75%; FP: 81%; [Bagalkot, India] A: median 28 y; M: 22% (all NLT); E: median 0 (0–10); NP: median 9 CPM (3–54); CF: median 3 (3–10); CLS: 78%; FP: 57%	[Bagalkot, India] gel use: 95% AWMP, 97% AWOP (last 7 d)
Cellulose sulfate vaginal gel (2004–2007)	Design and regimen: Phase 3, RCT: CS gel vs. PL (HEC gel), pa (immediately before), re-apply if no sex within 1 h. Intended outcome: 66 events → 50% HIV reduction. Follow-up (retention rate): 1 y FU (70% RET). Cohort (number, description): 1644 ♀, 18–35 y, (≥3 APW; ≥1 partner within last 3 m). Sites: 2 (Lagos and Port Harcourt, Nigeria); estimated HIV incidence was 5%/y. Baseline characteristics: A: μ 23 y; M: 95% not married; E: μ 10 y; NP: 18–21 last 3 m (15–17 new); CF: 5–6 APW	Stopped early when other CS trial [24] stopped Gel: 81% of all acts 7 d before monthly visit (50% of acts without condom) (SELF)

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	(at 7 d before screening); CLS: 60–61% (past 7 d); FP: 55–57% condoms; 20–21% none			
Carraguard vaginal gel (2004–2007)	Design and regimen: Phase 3, RCT: Carraguard vs. PL (methylcellulose gel), pa (≤ 1 h sex). Intended outcome: 194 endpoints $\rightarrow$ 33% HIV reduction. Follow-up (retention rate): 9–24 m FU (68% RET). Cohort (number, description): 6202 ♀, 16 y+, recruited from general population. Sites: 3 (Gugulethu, Western Cape [$n = 2315$], Soshanguve, Gauteng [$n = 2402$], Isipingo, Durban, KwaZulu-Natal [$n = 1485$], South Africa); estimated HIV incidence was 3.5%/y. Baseline characteristics: A: μ 31 y; M: 63% SNM, >98% had steady partner; E: μ 11 y (0–15); B: 80–82% ever gave birth; NP: 9% had other partners; CF: μ 2 APW (2 w before screening); AI: 2% (last 3 m); CLS: 34% AWMP, 62% AWOP; FP: >50% injectable HC. [Gugulethu, Western Cape] A: μ 33 y; M: 54% SNM; E: μ 10.5 y; NP: 3% other partners; CF: 2.2 APW; AI: <1% (ever); CLS: 37% AWMP, 52% AWOP; FP: 60% HC; [Soshanguve, Gauteng] A: μ 29 y; M: 66% SNM; E: μ 11.5 y; NP: 16% other partners; CF: 2.2 APW; AI: 1% (ever); CLS: 34% AWMP, 67% AWOP; FP: 47% HC; [Isipingo, Durban, KwaZulu-Natal] A: μ	Carraguard gel safe, not effective for HIV prevention	Gel: μ 96% at LS (SELF); CLS: μ 64% (SELF); Primary adherence measure: μ 42% “covered” sex acts (μ weekly insertions, per dye stain assay/μ weekly sex acts (SELF). [Gugulethu, Western Cape] Gel: μ 95% at LS (SELF); CLS: μ 68% (SELF); μ 27% covered acts; [Soshanguve, Gauteng] Gel: μ 98% at LS (SELF); CLS: μ 59% (SELF); μ 48% covered acts; [Isipingo, Durban, KwaZulu-Natal] Gel: μ 92% at LS (SELF); CLS: μ 58% (SELF); μ 55% covered acts	[26]

	30 y; M: 74% SNM; E: μ 10.8 y; NP: 8% other partners; CF: 1.3 AW; AI: 6% (ever); CLS: 30% AWMP, 50% AWOP; FP: 44% HC		
PRO-2000 vaginal gel (2003–2004)	Design and regimen: Phase 2, RCT (4-arms): 0.5% PRO-2000 gel vs. 2% PRO-2000 gel vs. PL (HEC gel) vs. control (no gel), bid/28 d, women instructed to wash vagina with water before inserting gel as per normal hygiene practice. Intended outcome: Safety and acceptability. Follow-up (retention rate): 28 d FU (69% RET). Cohort (number, description): 180 healthy and symptomatic ♀, 18–45 y. Sites: 1 (Kampala, Uganda). Baseline characteristics: A: μ 29 y; M: no information; E: 56% primary, 38% secondary; CF: 86% 2–3 APW, 14% $\geq$ 4 APW	Gel was safe and well-tolerated for bid use/4 w (move to Phase 3 recommended)	Overall adherence: 69% [27]
PRO-2000 vaginal gel (2005–2009)	Design and regimen: Phase 3, RCT: 0.5% PRO 2000/5 gel vs. 2% PRO 2000/5 gel vs. PL (HEC gel); pa ($\leq$ 1 h sex). Intended outcome: 90% power $\rightarrow$ 40% reduction HIV incidence. Follow-up (retention rate): 52 w overall FU, 104 w FU in Uganda (81% RET). Cohort (number, description): 9385 ♀, 16 y+. Sites: 6 (Durban, South Africa [2391 ♀, 18 y+, general population], Johannesburg, South Africa [n = 2499 ♀, 18 y+, recruited from general population], Masaka, Uganda [840 HIV-negative ♀ with HIV+ partner], Mwanza,	Did not show protective effect of 0.5% or 2% PRO 2000/5. HIV incidence at 52 w (+6) censored for pregnancy was 4.6 (4.2–5.1)	Gel used in μ 89% of LS; 58% ♀ classified as consistent gel users (defined as [1] gel LS $\geq$ 92% visits, [2] returned $\geq$ 1 used applicator when appropriate, and [3] attended $\geq$ 7/13 visits unless pregnant /HIV+). [Durban, South Africa] 89% gel use; 58% ♀ as consistent users; Johannesburg, South Africa] 85% gel use; 49%

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	Tanzania [1146 ♀, 16 y+, recruited from recreational facilities], Africa Centre, KwaZulu-Natal, South Africa [1177 ♀, 18 y+, recruited from general population], Mazabuka, Zambia [1332 ♀, 18 y+, recruited from general population]]; estimated HIV incidence was 4.0%/y. Baseline characteristics: A: μ 30 y; M: varied by site (see ahead); E: 23% $\geq$ secondary; NP: 1% >1 partner (last 1 w); CF: median 2 APW; AI: 1% (last 4 w); CLS: 57% (excludes 2% PRO 2000/5 gel arm); FP: 56% (effective method). [Durban, South Africa] A: μ 29 y; E: 31% $\geq$ secondary; NP: <0.5% >1 partner (last 1 w); CF: 2 APW; AI: 2% (last 4 w); CLS: 77%; FP: 65%; [Johannesburg, South Africa] A: μ 27 y; E: 44% $\geq$ secondary; NP: <0.5% >1 partner (last 1 w); CF: median 3 APW; AI: 1% (last 4 w); CLS: 71%; FP: 60%; [Masaka, Uganda] A: μ 32 y; E: 2% $\geq$ secondary; NP: 0% >1 partner (last 1 w); CF: median 1 APW; AI: <0.5% (last 4 w); CLS: 70%; FP: 27%; [Mwanza, Tanzania] A: μ 30 y; E: 5% $\geq$ secondary; NP: 3% >1 partner (last 1 w); CF: median 1 APW; AI: <0.5% (last 4 w); CLS: 33%; FP: 50%; [Africa Centre, KwaZulu-Natal, South Africa] A: μ 35 y; E: 20% $\geq$ secondary; NP: <0.5% >1		♀ as [consistent users; [Masaka, Uganda] 89% gel use; 59% ♀ as consistent users; [Mwanza, Tanzania] 92% gel use; 57% ♀ as consistent users; [Africa Centre, KwaZulu-Natal, South Africa] 94% gel use; 71% ♀ as consistent users; [Mazabuka, Zambia] 93% gel use; 68% ♀ as consistent users	

	partner (last 1 w); CF: median 2 APW; AI: 1% (last 4 w); CLS: 42%; FP: 50%; [Mazabuka, Zambia] A: μ 29 y; E: 7% $\geq$ secondary; NP: <0.5 >1 partner (last 1 w); CF: median 2 APW; AI: 1% (last 4 w); CLS: 20%; FP: 61%		
BufferGel and PRO-2000 vaginal gels (2005–2009)	Design and regimen: Phase 2/2 b, RCT (4-arm): BufferGel vs. PRO-2000 vs. PL (HEC gel) vs. no gel; 1 applicator pa (≤ 1 h). Intended outcome: 192 endpoints $\rightarrow$ 15.3–33% HIV risk reduction (to warrant further study). Follow-up (retention rate): 12–30 m FU, μ FU 20.4 m (93.6% RET). Cohort (number, description): 3101 ♀, 18 y+, ≥ 1 sex act (past 3 m), ≤ 2 sex acts/d (past 2 w). Sites: 8 (Blantyre, Malawi [$n = 441$], Lilongwe, Malawi [$n = 596$], Durban, South Africa [$n = 702$], Hlabisa, South Africa [$n = 346$], Philadelphia, PA, USA [$n = 200$], Kamwala, Zambia [$n = 319$], Chitungwiza, Zimbabwe [$n = 260$], Harare, Zimbabwe [$n = 223$]). Baseline characteristics: A: μ 26–27 y; M: 62–63%; E: 62–64% $\geq$ some secondary; CF: μ 2.8–3 acts (last 7 d); AI: 4–5% (ever), 1% (last 7 d); CLS: 67–69%; FP: 19–20% OC, 46–49% injectable HC. [Blantyre, Malawi] A: μ 26 y; E: 6% $\geq$ secondary; NP: 0% >1; CF: median 3 APW; AI: 1% (ever); CLS: 52%; FP: 87%; [Lilongwe, Malawi] A: μ 27 y; E: 3% $\geq$ secondary; NP: 0% >1; CF: median 2 APW;	Safe but not effective	81.1% at LS, [29] 69.1% in sex acts without condom (SELF); Condom use similar in gel arms (72%) but higher in no gel arm (81%) (SELF). [Blantyre, Malawi] 82.6% gel at LS; 64.7% without condom; [Lilongwe, Malawi] 75.4% gel at LS; 68.7% without condom; [Durban, South Africa] 79% gel at LS; 63.5% without condom; [Hlabisa, South Africa] 79.2% gel at LS; 61.7% without condom; [Philadelphia, PA, USA] 76.7% gel at LS; 56% without condom; [Kamwala, Zambia] 82.5% gel at LS; 81.6% without condom; [Chitungwiza, Zimbabwe] 93.5% gel at LS; 89.9% without condom; [Harare,

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	AI: 1% (ever); CLS: 55%; FP: 91%; [Durban, South Africa] A: μ 25 y; E: 39% $\geq$ secondary; NP: 4% >1; CF: median 2 APW; AI: 4% (ever); CLS: 77%; FP: 92%; [Hlabisa, South Africa] A: μ 25 y; E: 30% $\geq$ secondary; NP: 1% >1; CF: median 1 APW; AI: $<1\%$ (ever); CLS: 62%; FP: 75%; [Philadelphia, PA, USA] A: μ 35–36 y; E: 80% $\geq$ secondary; NP: 27% >1; CF: median 2 APW; AI: 46% (ever); CLS: 61%; FP: 89%; [Kamwala, Zambia] A: μ 23 y; E: 9% $\geq$ secondary; NP: 3% >1; CF: median 3 APW; AI: 3% (ever); CLS: 77%; FP: 98%; [Chitungwiza, Zimbabwe] A: μ 26 y; E: 29% $\geq$ secondary; NP: 3% >1; CF: median 5 APW; AI: 1% (ever); CLS: 87%; F: 99% [Harare, Zimbabwe] A: μ 27 y; E: 39% $\geq$ secondary; NP: 0% >1; CF: median 4 APW; AI: $<1\%$ (ever); CLS: 85%; FP: 99%		Zimbabwe] 91.0% gel at LS; 78.1% without condom	
1% tenofovir vaginal gel (2007–2010)	Design and regimen: Phase 2 b, RCT: 1% tenofovir gel vs. PL (HEC gel), 1 dose before sex (up to 12 h) plus 1 dose after sex (up to 12 h) and no more than 2 doses in 24 h (BAT24 regimen). Intended outcome: 92 endpoints → 90% power to detect 50% effect on HIV. Follow-up (retention rate): 30 m FU, monthly visits, μ 18 m FU per participant (95% RET). Cohort (number,	1% tenofovir gel reduced HIV risk by 39%; 54% in highly adherent women (defined as using gel in $>80\%$ sex acts)	Primary adherence measure: the proportion of sex acts covered by two doses of gel determined by monthly applicator count and SELF coital frequency. [eThekwini, KwaZulu-Natal, South Africa]	[30]

	description): 1085 ♀ enrolled and randomized, 18–40 y, sexually active (≥ 2 sex acts in last 30 d), HIV-uninfected; 889 ♀ analyzed. Sites: 2 (urban site: eThekweni, KwaZulu-Natal, South Africa [$n = 278$]; rural site: Vulindlela, KwaZulu-Natal, South Africa [$n = 611$]); estimated HIV incidence was 11.2%/y. Baseline characteristics: A: μ 24 y; M: 6% (88% stable partner); NP: μ 3–4 (lifetime); CF: 62% (last 7 d); AI: $<0.5\%$ (last 30 d); C: 29% always used; FP: 15% OC, 82% injectable HC. [eThekweni, KwaZulu-Natal, South Africa] A: μ 25; M: 4% (93% stable partner); NP: μ 6 (lifetime), 2.5% new partner (last 7 d); CF: 68.3% (last 7 d); AI: 0.4% (last 30 d); CLS: 42.8% always; FP: 79.9% injectable HC; [Vulindlela, KwaZulu-Natal, South Africa] A: μ 23; M: 6.5% (77% stable partner); NP: μ 2.1 (lifetime), 0.5% new partner (last 7 d); CF: 58.9% (last 7 d); AI: 0.5% (last 30 d); CLS: 22.9% always; FP: 83.1% injectable HC		median primary adherence: 50.0%; median SELF adherence: 84.0%; [Vulindlela, KwaZulu-Natal, South Africa] median primary adherence: 68.7%; median SELF adherence: 92.9%
1% tenofovir vaginal gel (2006–2007)	Design and regimen: Phase 2, RCT (4-arms): tenofovir gel (qd) vs. PL (HEC gel, qd) vs. tenofovir gel (pa) vs. PL (pa). Intended outcome: Safety and acceptability. Follow-up (retention rate): 6 m FU (96% RET). Cohort (number, description): 200 sexually-active ♀. Sites: 3 (India [$n = 100$], Birmingham,	1% tenofovir gel was safe and acceptable for qd use by HIV-negative ♀ over extended periods of time	80% adherence for coitally dependent use within 2 h of sex; 83% adherence of qd doses used. [India] 93% sex acts with gel use last 1 m (pa regimen); 72% gel used/d (qd regimen);

(Continued)

Table A.1 (Continued)

Product (date)	Trial features	Trial outcomes	Adherence outcomes	Refs.
	NY, USA [2 sites; $n = 100$]. Baseline characteristics: A: μ 32 y; M: 64%. [India] A: μ 33 y; M: 99%; E: 21% > 10 y; [Birmingham, NY, USA] A: μ 31; M: 28%; E: 63% > 12 y		[Birmingham, NY, USA] 80% sex acts with gel use in last 1 m (pa regimen); 75.5% gel used/day (qd regimen)	
Oral and topical tenofovir (2008–2010)	Design and regimen: Phase 2, OL (tenofovir tablet and gel), cross-over, 3 regimens: oral tablet qd $\times$ 3 w vs. vaginal gel qd $\times$ 3 w vs. both qd $\times$ 3 w, 1 w wash-out before cross-over, randomized to regimen order. Intended outcome: Adherence and acceptability. Follow-up (retention rate): 21 w FU (97–100% RET per visit). Cohort (number, description): 168 ♀, 18–45 y, sexually active (sex $\geq 4\times$ during 1 m before screening). Sites: 7 (South Africa [$n = 48$], Uganda [$n = 24$], United States [$n = 72$]). Baseline characteristics: A: μ 30.8 y; M: 40%; E: >60% $\geq$ secondary; NP: μ 1.4 (last 3 m); CF: 33% ≥ 3 APW (last 3 w); AI: 27% (ever); CLS: 48%. [South Africa] A: μ 31; M: 40%; E: 58% $\leq$ primary; NP: μ 1 (last 3 m); CF: 33% ≥ 3 APW (last 3 w); AI: 2%; CLS: 62%; [Uganda] A: μ 30; M: 96%; E: 87% $\leq$ primary; NP: μ 2.6 (last 3 m); CF: 71% ≥ 3 APW (last 3 w); AI: 0% (ever); CLS: 21%; [United States] A: μ 31; M: 21%; E: 81% attended college; NP: μ 1.2 (last 3 m); CF: 21% ≥ 3 APW (last 3 w); AI: 53% (ever); CLS: 48%	SELF adherence was 94% vs. 62–64% per serum levels; US ♀ favored tablet (72%), African ♀ had mixed preference (42% gel, 40% tablet)	94% (SELF); only 64% of women had serum levels consistent with taking a daily tablet. [South Africa] 39–44% (drug level), 59–60% inconsistent with drug levels by SELF; [Uganda] 39–50% (drug level), 50–58% inconsistent with drug levels by SELF; [United States] 81–84% (drug level), 8–14% inconsistent with drug levels by SELF	[32]

Oral and topical tenofovir and oral Truvada ^{®a} (2009–2012)	Design and regimen: Phase 3, RCT, double-blind (5-arms): oral tenofovir vs. oral Truvada [®] vs. PL (tablet) vs. 1% tenofovir gel vs. PL (HEC gel), qd. Intended outcome: HIV prevention. Follow-up (retention rate): ND. Cohort (number, description): 5029 ♀, HIV negative, heterosexual. Sites: 5 (South Africa [3 sites; <i>n</i> = 4077], Uganda [<i>n</i> = 322], Zimbabwe [2 sites; <i>n</i> = 630]). Baseline characteristics: [South Africa] A: μ 25 y; M: 8%; E: 54% $\geq$ secondary; [Uganda] A: μ 28 y; M: 50%; E: 3% $\geq$ secondary; [Zimbabwe] A: μ 28 y; M: 94%; E: 60% $\geq$ secondary	No effectiveness found; adherence was very low ($\approx$ 30% of ♀ never had any drug detected)	In a subsample of 773 participants, <1 out of 3 had drug detected in blood sample	[33]
Dapivirine vaginal ring (2010)	Design and regimen: Phase 2, RCT: dapivirine (25 mg) platinum catalyzed silicone vaginal ring vs. PL (non-medicated platinum catalyzed silicone vaginal ring), 1:1 randomization, wear ring for 3 consecutive 28-day periods, new ring each 28-day period, ring not to be removed between study visits. Intended outcome: Safety, acceptability, adherence and pharmacokinetics. Follow-up (retention rate): ND. Cohort (number, description): 280 ♀, HIV negative, healthy, sexually active. Sites: 10 (Kenya, Malawi, Tanzania, South Africa). Baseline characteristics: A: μ 26 y [18–40]; M: 22%; NP: 99% = 1 partner; 35% live with partner	Ring was safe and acceptable	SELF: 84% perfect adherence (ring never out); 92% with 100% daily adherence (ring never out $\geq$ 1 day); no clear relationship observed between plasma concentrations and residual amounts of dapivirine in used rings	[34–35]

Abbreviations: →, to measure; ♀, women; ♂, men; μ , mean/average; A, age; AE, adverse effects; AI, anal intercourse; ALP, after last partner; ALS, at last sex act;

APW, acts per week; AWC, acts with clients; AWMP, acts with main partner; AWOP, acts with other partners; AWP, acts with partners; B, parity; bid, twice per day; BS, before sex; C, condom; CF, coital frequency; CLS, condom at last sex; CPM, clients per month; CS, cellulose sulfate; CT, *Chlamydia trachomatis*; d, day; DS, dextrin sulfate; DSMC, Data and Safety Monitoring Committee; E, education; FP, contraception; FSW, female sex worker; FU, follow-up; h, hour; HC, hormonal contraception; HEC, hydroxyethylcellulose; LS, last sex; M, married/marital status; m, month; N-9, nonoxynol-9; ND, not defined; NG, *Neisseria gonorrhea*; NLT, not living together; NP, number of partners; OC, oral contraceptives; OL, open label; pa, per sex act; PL, placebo; PPM, partners per month; PPW, partners per week; qd, daily/once per day; qod, every other day; RCT, randomized controlled trial; RET, retention; SD, standard deviation; SELF, self-report; SNM, single/never married; SS, sample size; STD, sexually transmitted diseases; TL, tubal ligation; w, week; y, year.

^aTruvada[®]—oral emtricitabine/tenofovir disoproxil fumarate combination tablet (Gilead Sciences, Foster City, CA, USA).

References

1. Rosenberg, M. J., Rojanapithayakorn, W., Feldblum, P. J., and Higgins, J. E. (1987). Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial, *JAMA*, **257**, 2308–2312.
2. Louv, W. C., Austin, H., Alexander, W. J., Stagno, S., and Cheeks, J. (1988). A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections, *J. Infect. Dis.*, **158**, 518–523.
3. Niruthisard, S., Roddy, R. E., and Chutivongse, S. (1992). Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections, *Lancet*, **339**, 1371–1375.
4. Kreiss, J., Ngugi, E., Holmes, K., Ndinya-Achola, J., Waiyaki, P., Roberts, P. L., Ruminjo, L., Sajabi, R., Kimata, J., Fleming, T. R., Anzala, A., Holton, D., and Plummer, F. (1992). Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes, *JAMA*, **268**, 477–482.
5. Zekeng, L., Feldblum, P. J., Oliver, R. M., and Kaptue, L. (1993). Barrier contraceptive use and HIV infection among high-risk women in Cameroon, *AIDS*, **7**, 725–731.
6. Feldblum, P. J., and Weir, S. S. (1994). The protective effect of nonoxynol-9 against HIV infection, *Am. J. Public Health*, **84**, 1032–1034.
7. Weir, S. S., Feldblum, P. J., Zekeng, L., and Roddy, R. E. (1994). The use of nonoxynol-9 for protection against cervical gonorrhea, *Am. J. Public Health*, **84**, 910–914.

8. Roddy, R. E., Zekeng, L., Ryan, K. A., Tamoufe, U., Weir, S. S., and Wong, E. L. (1998). A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases, *N. Engl. J. Med.*, **339**, 504–510.
9. Richardson, B. A., Lavreys, L., Martin, H. L., Jr., Stevens, C. E., Ngugi, E., Mandaliya, K., Bwayo, J., Ndinya-Achola, J., and Kreiss, J. K. (2001). Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: A randomized clinical trial, *Sex. Transm. Dis.*, **28**, 394–400.
10. Roddy, R. E., Zekeng, L., Ryan, K. A., Tamoufe, U., and Tweedy, K. G. (2002). Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: A randomized controlled trial, *JAMA*, **287**, 1117–1122.
11. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegné-Traore, V., Uaheowitchai, C., Karim, S. S., Masse, B., Perriens, J., and Laga, M. (2002). Effectiveness of col-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial, *Lancet*, **360**, 971–977.
12. Kilmarx, P. H., van de Wijgert, J. H., Chaikummao, S., Jones, H. E., Limpakarnjanarat, K., Friedland, B. A., Karon, J. M., Manopaiboon, C., Srivirojana, N., Yanpaisarn, S., Supawitkul, S., Young, N. L., Mock, P. A., Blanchard, K., and Mastro, T. D. (2006). Safety and acceptability of the candidate microbicide Carraguard in Thai women: Findings from a phase II clinical trial, *J. Acquir. Immune Defic. Syndr.*, **43**, 327–334.
13. Bakobaki, J. M., Lacey, C. J., Bukonya, M. I., Nunn, A. J., McCormack, S., Byaruhanga, R. N., Okong, P., Namukwaya, S. W., Grosskurth, H., and Whitworth, J. A. (2005). A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda, *AIDS*, **19**, 2149–2156.
14. Carraguard Phase II South Africa Study Team (2010). Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa, *Contraception*, **82**, 563–571.
15. Kilmarx, P. H., Blanchard, K., Chaikummao, S., Friedland, B. A., Srivirojana, N., Connolly, C., Witwatwongwana, P., Supawitkul, S., Mock, P. A., Chaowanachan, T., and Tappero, J. (2008). A randomized, placebo-controlled trial to assess the safety and acceptability of use of Carraguard vaginal gel by heterosexual couples in Thailand, *Sex. Transm. Dis.*, **35**, 226–232.
16. Padian, N. S., van der Straten, A., Ramjee, G., Chipato, T., de Bruyn, G., Blanchard, K., Shiboski, S., Montgomery, E. T., Fancher, H., Cheng,

- H., Rosenblum, M., van der Laan, M., Jewell, N., and McIntyre, J. (2007). Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial, *Lancet*, **370**, 251–261.
17. Peterson, L., Nanda, K., Opoku, B. K., Ampofo, W. K., Owusu-Amoako, M., Boakye, A. Y., Rountree, W., Troxler, A., Dominik, R., Roddy, R., and Dorfänger, L. (2007). SAVVY (C31G) gel for prevention of HIV infection in women: A phase 3, double-blind, randomized, placebo-controlled trial in Ghana, *PLoS One*, **2**, e1312.
 18. Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., and Rountree, W. (2008). SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria, *PLoS One*, **3**, e1474.
 19. van der Straten, A., Moore, J., Napierala, S., Clouse, K., Mauck, C., Hammond, N., and Padian, N. (2008). Consistent use of a combination product versus a single product in a safety trial of the diaphragm and microbicide in Harare, Zimbabwe, *Contraception*, **77**, 435–443.
 20. von Mollendorf, C. E., Van Damme, L., Moyes, J. A., Rees, V. H., Callahan, M. M., Mauck, C. K., Puren, A. J., Tweedy, K., and Taylor, D. (2010). Results of a safety and feasibility study of the diaphragm used with Acidform gel or K-Y jelly, *Contraception*, **81**, 232–239.
 21. Joglekar, N. S., Joshi, S. N., Deshpande, S. S., Parkhe, A. N., Katti, U. R., and Mehendale, S. M. (2010). Acceptability and adherence: Findings from a phase II study of a candidate vaginal microbicide, “Praneem polyherbal tablet”, in Pune, India, *Trans. R. Soc. Trop. Med. Hyg.*, **104**, 412–415.
 22. Joshi, S. N., Dutta, S., Kumar, B. K., Katti, U., Kulkarni, S., Risbud, A., and Mehendale, S. (2008). Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: A phase II clinical trial report, *Sex. Transm. Infect.*, **84**, 343–347.
 23. Mbopi-Keou, F. X., Trottier, S., Omar, R. F., Nkele, N. N., Fokoua, S., Mbu, E. R., Domingo, M. C., Giguere, J. F., Piret, J., Mwatha, A., Masse, B., and Bergeron, M. G. (2010). A randomized, double-blind, placebo-controlled phase II extended safety study of two invisible condom formulations in Cameroonian women, *Contraception*, **81**, 79–85.
 24. Van Damme, L., Govinden, R., Mirembe, F. M., Guedou, F., Solomon, S., Becker, M. L., Pradeep, B. S., Krishnan, A. K., Alary, M., Pande, B., Ramjee, G., Deese, J., Crucitti, T., and Taylor, D. (2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission, *N. Engl. J. Med.*, **359**, 463–472.

25. Halpern, V., Ogunsola, F., Obunge, O., Wang, C. H., Onyejebu, N., Oduyebo, O., Taylor, D., McNeil, L., Mehta, N., Umo-Otong, J., Otusanya, S., Crucitti, T., and Abdellati, S. (2008). Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: Results of a phase III trial in Nigeria, *PLoS One*, **3**, e3784.
26. Skoler-Karpoft, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., Dozier, G., Maguire, R., and Lahteenmaki, P. (2008). Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial, *Lancet*, **372**, 1977–1987.
27. Kamali, A., Byomire, H., Muwonge, C., Bakobaki, J., Rutterford, C., Okong, P., Profy, A., Byaruhanga, R., Namukwaya, S., McCormack, S., Grosskurth, H., Nunn, A. J., and Lacey, C. J. (2010). A randomised placebo-controlled safety and acceptability trial of PRO2000 vaginal microbicide gel in sexually active women in Uganda, *Sex. Transm. Infect.*, **86**, 222–226.
28. McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A. M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., Mutemwa, R., Vallely, A., Palanee, T., Sookrajh, Y., Lacey, C. J., Darbyshire, J., Grosskurth, H., Profy, A., Nunn, A., Hayes, R., and Weber, J. (2010). PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial, *Lancet*, **376**, 1329–1337.
29. Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T. R., Piwowar-Manning, E., Masse, B., Hillier, S. L., and Soto-Torres, L. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women, *AIDS*, **25**, 957–966.
30. Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., and Taylor, D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, *Science*, **329**, 1168–1174.
31. Hillier, S. (2008). HPTN 059 expanded safety and acceptability study of the vaginal microbicide 1% tenofovir gel, *Microbicides 2008*, New Delhi, India.
32. Minnis, A. M., Gandham, S., Richardson, B. A., Guddera, V., Chen, B. A., Salata, R., Nakabiito, C., Hoesley, C., Justman, J., Soto-Torres, L., Patterson, K., Gomez, K., and Hendrix, C. W. (2013). Adherence and acceptability

- in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women, *AIDS Behav.*, **17**, 737–747.
33. Marrazzo, J. M., Ramjee, G., Nair, G., Palanee, T., Mkhize, B., Nakabiito, C., Taljaard, M., Piper, J., Gomez, K., and Chirenje, M. (2013). Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the voice study (MTN 003), *20th Conference on Retroviruses and Opportunistic Infections*, Atlanta, GA, USA.
 34. Nel, A., Kamupira, M., Woodsong, C., van der Straten, A., Montgomery, E., van Niekerk, N., and Nuttall, J. (2012). Safety, acceptability and pharmacokinetic assessment (adherence) of monthly dapivirine vaginal microbicide rings (ring-004) for HIV prevention, *19th Conference on Retroviruses and Opportunistic Infections*, Seattle, WA, USA.
 35. van der Straten, A., Woodsong, C., Montgomery, E., Cheng, H., and Nel, A. (2012). High adherence and acceptability of a monthly dapivirine vaginal ring for HIV prevention in Africa, *2012 International Microbicides Conference*, Sydney, Australia.

Index

- α -1,2-mannose disaccharide 422
- 1% TFV gel 12, 61, 66, 69–70, 159, 163, 201, 243, 257, 359, 471
- 2 RANTES 432–33
- 2F5 95, 227, 239
- 2G-S16 422
- 2G12 95, 227
- 4E10 95, 227
- 5p12-RANTES 95, 520
- 6P4-RANTES 95
- 90% effective concentration (EC₉₀) 427
- 90% inhibitory concentration (IC₉₀) 63
- 92BR025 519
- 98IN007 519
- ^{99m}TcTechnetium-sulphur colloid 344
- ¹¹¹Indium-oxine 345

- Abacavir 226
- Absorption 198, 207, 249, 258, 262, 297, 341, 417, 490–91, 554, 559, 575–76
- Abstinence 118, 195, 589–90
- Acacia gum 234, 236
- Accelerated review 561
- Acceptability 259–60, 293–95, 335–37, 343, 348–50, 352–53, 467, 571–72, 574–76, 584–85, 589, 596, 598–99, 638–39, 647–49
- Acetate buffer 234, 245, 391
- Acid phosphatase 65, 388
- ACIDFORM® 58, 200, 203
- Acidifying agents 126–27, 300
- Acquired immunodeficiency syndrome (AIDS) 331, 420
- Activator protein 1 124
- Active compounds 198, 201, 206, 431, 466, 468, 474–75, 483, 491
- Active pharmaceutical ingredient (API) 576
- Active transport 333
- Acts of sex 589, 591
- Acyclovir (ACV) 238, 474
- Acyclovir monophosphate 438
- Adherence 128, 130, 222–24, 349, 353–55, 360, 463–64, 469, 569–90, 596–604, 629–30, 634–36, 638–40, 642–44, 646–49
- Adherence-based futility 579
- Adherence behavior 360, 572, 577
- Adherence counselor 579
- Adherence measurement 601
- Adherence measures 570, 579
- Adherence support team 578
- Adhesive bonding 313, 435–36
- Adolescents 119, 588, 599–600
- Adverse effects (AEs) 342
- Aerosols 203
- Affordability 196, 442, 535–36, 540–41, 544
- Agarose 60, 314
- Air/ liquid interface 60
- Alginate 379–80, 438
- Algorithm 59, 65, 119, 127, 130, 338, 342, 557
- Amdoxovir 226
- American Foundation for AIDS Research (amfAR) 346

- American Type Culture Collection (ATCC) 122
- Aminopeptidase 297
- Amorphous phase 468
- Amphiphilic 383, 466
- Amyloid fibrils 65, 392
- Anal sex 334–36, 346, 590–91
- Anestrus 249–50
- Animal model 66, 177, 249, 254, 316–17, 524
- Anionic polyanions 300
- Anisotropy 486
- Anti-CD4 monoclonal antibodies 513
- Anti-foaming agents 304
- Anti-HIV activity 62, 136, 204, 314, 437, 463
- Anti-HIV neutralizing antibodies 423
- Anti-ICAM-1 Fabs 517
- Anti-sperm activity 475
- Antibodies 58, 94–95, 104, 118, 226–27, 238, 266, 378, 419, 423, 470, 513, 516–17
- Antibody fragments 239
- Antigen presenting cells 333
- Antimicrobial mediators 126
- Antimicrobial peptides 470
- Antiretroviral (ARV) 91, 194, 222, 302, 349, 416, 460, 549, 571
- Antiretroviral therapy (ART) 225, 576
- Antiviral 58–59, 62–64, 98–99, 248, 391–93, 415–16, 418, 420, 422, 432, 460, 471, 511, 513–14, 516–19
- Apical surface 100, 342
- Apparatus 4, flow-through cell system 179
- Apparent permeability coefficient 441
- Applicator 292, 294, 299, 308, 341, 344, 347, 537, 539–41, 570–71, 598, 601, 640, 643, 645–46
- Aptamers 385
- APTV-CV-N (P51G) 514
- Aqueous-based gels 60
- Aqueous phase 235, 424, 463
- Area under the curve (AUC) 261, 356
- Article 58 Procedure 562–63
- ARV activity 426
- ARV agents 202, 226–27, 236, 239, 250, 255, 416, 418, 420, 429, 463, 465, 469, 598
- ARV-based microbicide 496, 576
- ARV drug 98–99, 103, 202, 206, 222, 225, 357, 360, 466, 469, 575
- ASPIRE 96, 104, 261, 542
- Atazanavir 226
- Atopobium vaginae* 129
- ATP-binding cassette (ABC) transporters 99
- B cells 57
- b12 95, 227
- Bacterial biofilms 253
- Bacterial colonization 130–31, 133, 296
- Bacterial vaginosis (BV) 122, 298
- Bacteriophage *qadh* 517
- BaL virus 473
- Basal epithelia 429
- Basket dissolution method 311
- BAT24 302, 571, 575, 591, 602, 646
- Batch size 537–40, 544
- Benefit/risk 550, 553, 555–56, 558, 561–62
- Benzalkonium chloride (BZK) 231
- Benzhydrylamine amide 421
- Betulonic acid 234

- BI 224436 226
- Bio-behavioral strategies 570
- Bioactivity 152, 238, 300–1, 313, 315, 342, 473, 480, 492
- Bioadhesion 311
- Bioavailability 100, 355, 377, 462, 482
- Biocompatibility 197, 313, 423, 556
- Biodistribution 72, 232
- Bioequivalence 244, 536
- Biological stimuli 379, 386
- Biomarker 65, 122, 126–27, 355, 383
- Biomarkers of adherence 570
- Biopolymers 465, 484, 497
- Biopsy 56, 61–62, 72, 173–74, 177, 180, 251–52
- Blister card with multiple units 309–10
- Blood 57–59, 230, 232, 241, 295, 300–1, 347–48, 355–56, 387, 391, 426, 429, 570, 572, 580
- BMS-806 95, 98
- BMS-378806 200
- BMS-599793 200
- BMS-663068 226
- Bone marrow/liver/thymus (BLT) mice 68
- Bovine serum albumin (BSA) 239, 490
- Box-Behnken experimental design 434
- Broad-spectrum microbicides 126, 225, 227
- Broadly neutralizing antibodies (BrNAbs) 58, 227, 470
- BspA 517
- BufferGel® 58, 203
- Buffering agents 58, 74, 200
- Buffering capacity 341, 388, 470–71
- Burst effect 229, 241, 432
- Burst release 229, 233, 235, 261, 394, 469, 477–79
- 2-Butyl acetate 354
- c-Jun N-terminal kinases 124
- C-peptide fusion inhibitors 516
- C-type lectin receptors 124
- C1C5-RANTES 512, 518–20
- C5A 204–6
- C31G 56, 126, 200
- C34 341, 512, 516, 521
- Caco-2 cells 427
- Candida* spp. 130
- Capital investment 494, 498
- CAPRISA (Centre for the AIDS Programme of Research in South Africa) 94
- CAPRISA 004 91, 96, 103, 128, 201, 222, 236, 238, 257, 302, 357, 359, 571–72, 575–77, 589–90
- Capsules 201, 244, 291
- Carbomer (Carbopol®) 421, 632
- Carbopol® 176, 203, 301, 305, 392
- Carbopol® 934 301
- Carbopol® 974P 176
- Carboxymethyl-dextran 382
- Carcinogenicity 119, 555
- Carrageenan 72, 203, 304–5, 574
- Carreau-like model 158–59, 163
- Carreau model 158–59
- CaSki cells 426–27
- Cathepsin G 122
- Cationic lipids 431
- Cationic peptides 64
- Cats 248, 254
- CbsA signal sequence 514–15
- CCR5 58, 67, 94–95, 98, 199, 202, 255, 333, 352, 356, 426, 429–30, 475, 512–14, 517–20
- CCR5 antagonism 518, 520

- CCR5 antagonist 356, 475, 518–20, 526
- CCR5 binding 95, 517
- CCR5-expressing cells 429
- CCR5-tropic (R5) 58, 301, 475, 514
- CD3 136, 347
- CD4 58, 60, 64, 67, 92–95, 99–102, 119–21, 123, 131, 133, 347, 430, 512–13, 517, 519
- CD4⁺ cells 120–21, 123, 131, 133
- CD4⁺ T cells 58, 60, 64, 67, 92–94, 99–100, 102, 152, 223, 297
- CD8 347
- CD34 68
- CD38-expressing NK cells 128
- CD44 389
- CD45 136
- CD68⁺ macrophages 60
- CD73 389
- Cell-associated HIV 344, 419, 422–23, 516
- Cell-associated virus 57, 151, 333, 421, 523
- Cell-based assays 56, 313, 422
- Cell-free virus 151, 333
- Cell lines 59–60, 65, 122, 132–33, 314, 422, 424, 426, 430
- Cell membrane transporters 99
- Cell membranes 101, 386, 426, 428, 437
- Cell monolayer 249, 427
- Cell transfection 430
- Cellular toxicity 338, 516
- Cellulose 56, 126, 128, 166, 203, 222, 300, 305, 470, 472, 570, 574, 638, 640–41, 650
- Cellulose acetate phthalate (CAP) 128, 300, 432, 470, 472
- Cellulose sulfate (CS) 56, 570
- CEM-SS cells 314
- Cenicriviroc (TBR-652) 226
- Center for Sexual Health Promotion 334
- Certificate of Pharmaceutical Product (CPP) 563
- Cervical mucus 161, 295, 297–98, 388, 390
- Cervical Mucus Simulant (CMS) 298
- Cervicitis 120
- Cervicovaginal 93, 100–2, 121–22, 126–27, 223–24, 243, 316–17, 355–56, 358, 388, 393, 416, 436, 439, 483
- Cervicovaginal fluid 243, 356, 436
- Cervicovaginal lavage (CVL) 63, 243
- Cervicovaginal mucosa 511
- Cervicovaginal mucus 393, 416, 439
- Cervicovaginal secretions 121–22, 126, 223–24, 248, 388
- Cervicovaginal toxicity 433
- Cervicovaginal tract 223, 251, 317
- Cervix 161, 204, 252, 296, 388, 431
- Cetyltrimethylammonium bromide (CTAB) 425
- Channel flow geometry 162–63
- CHARM-01 350
- CHARM-02 350
- Chemical instability 491
- Chemical stimuli 379
- Chemokines 120–21, 123, 131, 352, 475, 517, 519
- Child-bearing 555
- Chimpanzees 254
- Chitosan 305, 379–80, 423–24, 489
- Chlamydia 339, 650
- Chlorhexidine (CH) 231
- CHO cells 518
- Cholesterol 259, 390, 431, 433
- Cholesterol conjugates 431
- Chronic safety 555
- Circumcision 118, 594
- Citric acid 537–38

- Clade B 58, 71, 519
- Clade C 71, 519
- Class IV USP apparatus 311
- Clearance rate 173
- Clinical development program
 - 553, 556, 560
- Clinical evaluation 125, 230, 241,
 - 254, 256, 258, 260, 303, 334, 516, 536
- Clinical isolates 59
- Clinical packaging 542
- Clinical services 597, 600
- Clinical supply 542, 544
- Clinical translation 493
- Clinical trial 94–95, 231–32, 238,
 - 246–47, 258–59, 261–65, 536, 570, 572–74, 576–79, 589–90, 596–97, 601, 603, 650
- Clinical trial application (CTA) 554
- Clinical trial lot scale 264
- Clinical trial settings 572–73,
 - 578–79, 589, 601
- Clinical trial sponsors 581
- CMPD167 98, 232, 395
- CMPD176 226
- CMX-157 226
- CNT 99
- CNT2 102
- Co-axial nozzles 496
- Co-solvent 245, 307, 484
- Coated area 155, 162–64, 166,
 - 175, 183
- Coaxial electrospinning 462–63,
 - 470
- Coaxial fibers 463, 499
- Co-cultures 62, 70, 72–74
- Coital-associated trauma 350
- Coital frequency 571, 646, 650
- Coital shearing 429
- Coitally dependent
 - (coitus-dependent) 208, 293, 552, 575, 594, 647
- Coitally independent (coitus-independent) 224, 417
- Coitus 59, 64, 67, 157, 196,
 - 201–2, 207, 249, 333, 395, 637
- COL-1492 339
- Colloid systems 435
- Colloidal instability 425
- Colonic content 341
- Colorectal explant 98, 334, 338–40
- Colorectum 161
- Colposcopic observations 262, 316
- Colposcopy 119, 125, 252
- Combination formulations 71
- Combination HIV-1 Antiretroviral Rectal Microbicide (CHARM) Program 349
- Combination microbicide 240,
 - 243, 262
- Combined delivery 242, 463
- Commensal bacteria 509–13,
 - 515–17, 519–21, 523, 525–26
- Commercial manufacture 536,
 - 540, 544
- Commercial supply 535, 544, 546
- Commercialization plan 493, 498
- Common Technical Document (CTD) 564
- Community-based distribution (CBD) 600
- Community beliefs 580–81
- Compatibility 99, 293, 304–7, 314,
 - 342, 466, 493, 498, 574
- Complementary DNA (cDNA) 92,
 - 513
- Compliance 103, 201–2, 206–8,
 - 293, 390, 395, 498, 545, 554, 582, 629, 631–32, 640
- Composite fiber blends 466
- Compressed drug core 237
- Concanavalin-A 420
- Concentration gradients 154
- Concentration targets 247
- Condom 118, 195, 208, 221,
 - 336–38, 558, 582–84, 586,

- 594–96, 598, 631–33, 636–38, 640–41, 645–46, 650
- Condom promotion programs 584
- Conductivity 485
- Confocal fluorescence microscopy 424
- Confocal Raman spectroscopy 177, 180
- Conjoint analysis (CJA) 336
- Conservation of momentum 153
- Constitutive equation 157–58, 161
- Contact angle 181, 487
- Continuous roll dispenser 309–10
- Contraception 75, 204, 221, 258, 266, 295, 390, 419, 432, 463, 465–66, 573, 576, 600, 650
- Contraceptive 202, 204–5, 228–31, 239–44, 246–47, 258–60, 291–92, 294–95, 299–300, 386–87, 431–32, 596, 599–600, 602, 650
- Contraceptive practices 137
- Contraceptive Research and Development (CONRAD) 125
- Contract manufacturing 263, 498, 539
- Contract manufacturing organizations (CMOs) 263, 498
- Controlled release 206, 208, 231, 377–78, 380, 385, 390, 464, 479, 542, 575
- Convection 154–55, 170
- Copolymers 379, 381, 394
- Core requirements 564
- Core-shell fibers 496
- Core-shell nanogels 384
- Core solution 462
- Cost-effectiveness 598
- Coumarine-6 430
- Cream 257
- Critical entanglement concentration 484
- Critical viscosity 484
- Cross-linking 157, 393, 434, 488
- Crystalline compounds 462
- Crystallinity 465, 479, 482, 486, 490
- CSIC 226
- Cumulative release 61, 229–30, 232
- Current good manufacturing practice (cGMP) 197
- CXCR4 58, 202, 301, 333, 513–14
- CXCR4-tropic (X4) 58, 301, 514
- Cyanovirin-N (CV-N) 168, 513
- Cyclic changes 295
- cyclin T1* 67
- Cyclodextrins 304, 380, 417
- Cyclophilin inhibitors 226
- Cynomolgus macaque (*Macaca fascicularis*) 316
- Cytochrome P450 (CYP) 102
- Cytotoxicity 65, 205, 377, 392, 427–28, 432, 441
- Dapivirine (TMC120) 96, 170–72, 231–35, 240–42, 245, 260–63, 266, 301–2, 314–15, 425–27, 441–42, 466–67, 541–45, 575–76, 649
- Dapivirine film 301–2, 467
- Dapivirine vaginal ring 541–44, 550, 649
- Darunavir 101, 226, 466
- Data and Safety Monitoring Board (DSMB) 257
- Data package 557, 559, 561
- Declaration of Helsinki 560
- Degradation 103, 122–23, 236, 242, 293, 385, 390, 417–18, 464, 478, 488, 514, 519, 577
- Delavirdine 226
- Deleterious effects 67
- Delivery channels 237, 264, 597, 599

- Delivery rate 224
- Delivery system 203–7, 293, 295–97, 303, 383, 395, 417, 493, 520, 546
- Delivery vehicle 153, 470, 574
- Dendrimers 391, 420–22
- Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) 94, 333, 422
- Dendritic cells (DCs) 57, 315, 422
- Deoxycytidine kinases 355
- Dependent variables 154
- Depo-Provera® 69, 232–33
- Desmoglein 66
- Detergent-based microbicides 124
- Detergents 127, 300, 492
- Developed world 335, 550, 560, 565
- Developing countries 56, 193, 195, 197, 205, 550, 561–63, 565
- Developing world 195, 263, 335, 536, 539–40, 546, 563
- Development programs 550–51, 556–59
- Developmental safety 555
- Diaphragm 127, 204–5, 296, 584, 592, 596, 636, 638–39
- Diaries 354, 570, 582
- Didanosine 226
- Dielectric constant 490
- Differential scanning calorimetry (DSC) 306, 476
- Differential thermal analysis (DTA) 311
- Diffusion 168–70, 172–73, 178–80, 231–33, 235–36, 240, 314–15, 424–25, 429, 436, 438–39, 464, 468, 479, 487–88
- Diffusion coefficient 169–70, 173, 178, 180, 382
- Diffusion-controlled behavior 232
- Diffusion controlled release 464, 479
- Dioleoyl trimethylammonium propane (DOTAP) 438
- Diphosphopyridine nucleotide-diaphorase 389
- Disintegrants 303–4
- Disintegration testing 311
- Disintegration time 311
- Dispersing agents 292
- Dissolution 179, 182, 207, 235, 244–45, 292, 307, 311, 394–95, 463–64, 473, 476, 482–83, 487–88, 492
- Distribution system 545
- DL*-norgestrel 258
- DNA oligonucleotides 385
- Dolutegravir 226
- Dosage cost 494, 498
- Dosage form 203, 207, 291–95, 303, 309–10, 316–18, 341–42, 462, 464–65, 467–69, 483, 485, 546, 551, 554
- Dose-response 481
- Dose selection 358, 556
- Dossier filing 552, 560, 563, 565
- Double-emulsion/solvent evaporation method 430
- Douches 299, 346
- Draining lymph nodes 58, 93
- Drug absorption 249, 258, 341, 417, 554
- Drug association efficiency 423–24
- Drug carriers 380, 386–87, 416, 421, 499
- Drug combinations 75, 98, 101, 103, 236, 243, 248, 465, 550
- Drug concentration 61, 154, 173, 177, 180, 206, 222, 418, 492
- Drug content 307, 311, 342, 471, 478, 489
- Drug content uniformity 307
- Drug delivery 91–92, 151–56, 181–84, 203, 291–93, 295–98,

- 377–80, 385, 394–95, 459–60,
- 462–66, 468–70, 490–94,
- 498–99, 509–12
- Drug delivery systems 194, 196,
- 203, 291, 298, 460, 488
- Drug delivery vehicle 153, 470
- Drug distribution 92, 99, 101–2,
- 247, 341, 437
- Drug dosage forms 67, 161, 435
- Drug–drug interactions 92, 98,
- 261, 560–61
- Drug-eluting fibers 431, 498
- Drug labels 556
- Drug levels 59, 62–63, 243, 348,
- 354, 357, 418, 424, 426–27,
- 460, 462, 570, 572, 588, 648
- Drug loading 224, 228–30, 242,
- 381–83, 391, 423–25, 468,
- 471, 483, 486, 488–89, 491
- Drug metabolism 180, 254
- Drug permeability 179, 427
- Drug–polymer interactions 491
- Drug polymorphs 490
- Drug recrystallization 482, 491
- Drug release 170, 179, 341, 386,
- 394–95, 417, 434–35, 460,
- 464–66, 469–70, 472–73,
- 476–80, 483, 488, 491–92
- Drug resistance 71, 91, 383, 471
- Drug resistance-associated
- mutation 71
- Drug resistant 340
- Drug stability 417, 493
- Drug synergy 465
- Drug targeting 387, 416–17
- Drug transport 151–56, 158, 160,
- 162, 164, 166, 168, 170,
- 172–74, 176, 178, 180,
- 182–84, 468–69, 471
- Drug transport processes 461
- Dry sex 594
- Drying rate 307
- Drying step 307
- Drying temperatures 306
- Drying time 308
- Dryness 335, 467
- Dual-chamber 59, 66, 134–35
- Dual compartment microbicides
- 336
- Dual-sensitive 392
- E-cadherin 66, 132
- E. coli* 130–31, 512–14, 519,
- 521–22
- E. coli* Nissle 1917 512, 521
- E3 ligases 124
- Early-stage clinical trials 557
- Ect1/E6E7 cells 122, 132
- Ectocervical 99, 122, 246, 314–16,
- 338, 342, 391, 429, 438, 460,
- 480, 492
- Ectocervix 57, 132, 296–97, 314,
- 430
- Edema 135
- Education 334, 578, 588, 598, 602,
- 633, 640, 650
- Efavirenz 226, 255, 427
- Effectiveness 256, 259, 302,
- 336–37, 353, 355, 357, 360,
- 541, 559, 570–72, 575–76,
- 578–86, 589–90, 601
- Effectiveness clinical trials 584
- Efficacy 56, 58–59, 61–63, 70–72,
- 74–75, 94–98, 118–21,
- 125–28, 222–25, 246–51,
- 253–61, 313–16, 352–55,
- 357–58, 558–59
- egfp* 430–31
- Ejaculate 57, 65, 72, 333, 471
- Ejaculation 299, 394, 419, 424,
- 432, 439, 471, 473, 591
- Elastic modulus 311–12, 486
- Elastic squeezing model 165
- Elasticity 160, 303, 313
- Elastomer 204, 206, 224, 228–30,
- 232–33, 235–36, 240–41, 245,
- 254, 260, 263, 265
- Elcometer 4340 308

- Electric field 379, 460–61, 485, 496–97
- Electric forces 461
- Electroporation 517, 523
- Electroporation-derived transformants 517
- Electrospinnable polymers 465
- Electrospinning 431–32, 460–71, 473–77, 479–81, 484–85, 489–90, 493–99
- Electrospinning parameters 485
- Electrospun fibers 459–60, 462, 464–70, 472, 474–76, 478–80, 482, 484–86, 488–90, 492, 494–99
- Electrostatic interactions 426
- Elemental analysis 489
- Elimination 265, 484, 526, 554
- Elite controllers 118
- Elongation at break 311–13
- Elongation rollers 308
- Elvitegravir 199, 226
- Emtricitabine (FTC) 222, 341, 572
- Emulsion electrospinning 463, 469
- Emulsions 466, 482
- End1/E6E7 cells 122, 132
- Endocervical 122, 424
- Endocervix 57, 132, 249, 252, 296–97, 430
- Endometrium 430
- Endothermic peaks 490
- Enema 128, 343–44
- Enfuvirtide (T-20) 226
- Engineered lactobacilli 516
- Enhanced green fluorescence protein 430
- ENT 99
- ENT1 100–2
- ENT2 101–2
- Enterococcus* 131
- Entry inhibitor 168, 199, 226, 301
- Env-SHIV 255
- Enzymatic cleavage 429
- Enzyme-sensitive 387, 389
- Epithelial barriers 119
- Epithelial compatibility 342
- Epithelial damage 128, 135, 338
- Epithelial erosion 135
- Epithelial integrity 66, 125, 235, 316, 492
- Epithelial layer 57, 60, 93, 135, 251, 297, 429
- Epithelial penetration 416, 429
- Epithelial shedding 441
- Epithelial sloughing 128, 316, 352
- Epithelial surfaces 119, 152, 435
- Epithelial thickness 251–52
- Epithelial tissue 133, 464
- ermB* 515
- Erosion 119, 135, 258, 464, 467, 469, 476, 478–79, 488, 499
- Estrogen 161, 243, 250, 296–97
- Estrous cycle 249
- Ethanol 300, 394, 424, 462, 484
- Ethical implications 583
- Ethical standards 560
- Ethics committee 560
- Ethosomes 391
- Etravirine (ETR) 466
- Eubacterium* 131
- Eudragit® S 100 (ES 100) 394
- European Medicines Agency (EMA) 550
- Ex vivo challenges 74
- Ex vivo tissue models 314
- Excipient 133, 232, 293, 303–5, 307, 341, 394, 556
- Excipient combinations 133
- Excipient compatibility 293, 307
- Exothermic peaks 490
- Expanded safety clinical trials 584–85
- Explant 59–61, 65, 72, 93, 97–98, 235, 314–15, 334, 338–40, 348–49, 358–59, 480
- Exposure route 57
- Extensional viscosity 461, 484
- Extracellular matrix 389
- Extracellular signal-regulated kinases 124

- Face-to-face interviews 582
- FACTS 001 96, 536
- Fast dissolving 167, 303
- Fast release 432
- Feline immunodeficiency virus (FIV) 254
- FEM-PrEP 222, 266, 354, 357, 469, 572, 587–88
- Female condoms 197, 222, 597
- Female-controlled method 118
- Female genital tract 57, 59, 63, 74, 129, 132, 250–51, 295, 314
- Female hygiene products 299
- Female sex workers (FSWs) 582
- Female-to-male transmission 193
- Ferrous gluconate 234
- Festinavir 226
- FI-1 516
- FI-2 516
- FI-3 516
- Fiber-based microbicide 493–94, 498
- Fiber beading 485
- Fiber core 462
- Fiber meshes 431–32, 474, 477, 481, 496–97
- Fiber stiffness 486
- Fibroblast 246
- Fillers 303
- Film 153, 166–67, 182, 291–95, 299–318, 382, 388, 434, 467, 479, 482, 493–94, 497, 630, 632
- Film assessments 310
- Film casting speed 308
- Film-forming polymers 303, 307, 313
- Film formulation 292, 299–305, 307–8, 310–11, 313, 315
- Film packaging 309
- Finite volume conditions 483, 492
- First-generation microbicide 574
- First-in-human studies 553–54
- Flavor agents 303
- Flexibility 197, 202, 236, 266, 303, 316, 578
- Flexible sigmoidoscopy 351
- Flow consistency index 159
- Flow rates 162, 246, 497
- Flow-through method 246
- Fluid convection 154
- Fluid dynamics 437
- Fluid mechanics 156
- Foams 203, 207, 341, 459
- Fold endurance 311–13
- Folding endurance 308
- Follicle-associated epithelium 94
- Food and Drug Administration (FDA) 70, 120, 133, 225, 291, 482, 550, 597
- Forced sex 591
- Foreskin 57
- Formulation development 206–7, 535–36, 538, 540, 542, 544, 546, 552
- Formulations 56–57, 61, 70–71, 103–4, 127–28, 193–98, 206, 302–4, 377–78, 384–88, 390–92, 394–96, 482–84, 492, 588–92
- Fornix 160–61, 252
- Founder CD4⁺ T cells 93
- Founder population 57–58, 92–93
- Founder virus 333
- Fourth-generation dendrimer 421
- Fragrances 303
- Franz cell 59, 179
- Free-surface electrospinning 494, 497–98
- Fusion inhibitor 98, 341, 516
- Fusobacterium* 131
- Gag 97
- Gag-pol 97
- Gamma chain receptor 68
- Gardnerella vaginalis* 129

- Gastrointestinal tract (GIT) 380
- Gel 66, 126–31, 153–70, 172–77, 179–83, 302, 342–50, 353–59, 441, 536–41, 571–72, 574–76, 584–88, 594–96, 630–49
- Gel design 174, 183
- Gel dilution 159, 161–62, 164–65, 172, 179, 182
- Gel-foam rafts 60
- Gel insertion 155, 163, 173, 177, 575, 591
- Gel permeation chromatography (GPC) 479
- Gel spreading 164, 176, 181, 468
- Gel viscosity 157
- Gelatin 304, 379
- Gender-based differences 194
- Gender norms 595–96, 603
- Gene expression 67, 431, 520, 523
- Gene knockdown 431
- Gene silencing 430–31, 438
- Generally recognized as safe 482
- Generally regarded as safe (GRAS) 510
- Genetic material 417, 430
- Genetically modified organisms (GMOs) 299, 510
- Genital co-infections 194
- Genital tract 56–59, 62–63, 66, 73–74, 117, 129, 132, 250–51, 295–97, 314, 317, 416, 419, 427, 430–31
- Genital ulcers 60
- Genitourinary events 262
- GHOST cells 59
- Glacial acetic acid 464
- Glass transition temperature 304, 482
- Glass transitions 490
- Glucuronidase 388
- Glycan residues 168
- Glycerin 204, 342, 537–38
- Glycerol (see glycerin) 104, 128, 235, 265, 298, 305, 431, 465, 467, 470, 474
- Glycerol monolaurate (GML) 470, 474
- Go/No Go 127, 182
- Goblet cells 161
- Gold nanorods 384–85
- Gold NPs 385, 387, 422
- Goniometers 182
- Gonorrhea 650
- Governing equations 152–54
- gp41 126, 301, 419, 473, 512, 516, 521
- gp41 inhibitors 126, 301
- Griffithsin 126, 470
- GS-7340 63, 226
- Gut-associated lymphoid tissue (GALT) 58, 352
- Half-maximal effective concentration (EC_{50}) 246, 421, 482
- Half-maximal inhibitory concentration (IC_{50}) 72, 97, 170, 232, 492
- Half-maximal tissue culture infectious dose ($TCID_{50}$) 69, 256
- Hanging drop 182
- Hardness 304
- Healthcare system 574
- HEC-1-A cells 59, 66
- HeLa-CD4-CXCR4 cells 513
- HeLa cells 427, 513
- Hematopoietic stem cells (HSC) 68
- Hemolysin-A 521
- Heparin 434
- Hepatic first-pass effect 295
- HepG2 hepatocytes 430
- Heptad repeat-2 region 516
- Herpes simplex virus (HSV) 59, 235, 462
- Herpes simplex virus type 2 (HSV-2) 201, 226, 466

- Herschel–Bulkley model 157, 162
 Heterologous DNA fragment 525
 Heterologous proteins 510, 520
 Heterosexual transmission 193,
 221, 256, 333
 High-resolution anoscopy 351
 High-voltage source 461
 Highly active antiretroviral therapy
 (HAART) 70, 97, 117, 227,
 465
hIL-10 525
 Histological analysis 433
 HIV-1 target cells 333
 HIV-1 transmission 130, 198,
 242, 256, 314–15, 332, 342,
 392, 430, 511, 515, 518–19,
 521–22
 HIV-1_{BaL} 514, 519
 HIV-1_{HxB2} 513
 HIV-1_{IIIB} 314, 514
 HIV-1_{JR-CSF-GFP} 521
 HIV-1_{JR-FL} 513
 HIV-1_{NL4.3-GFP} 521
 HIV-1_{RF} 521
 HIV-1_{SF162} 519
 HIV-1_{92/HT/599} 314
 HIV/AIDS epidemics 194
 HIV challenge 60–62, 471
 HIV discordant relationships 586
 HIV incidence 56, 221, 571, 582,
 586, 631–32, 634, 637–38,
 640–44, 647
 HIV infection 64–65, 67, 93–95,
 118, 194–97, 222–25, 227,
 231, 239, 242–43, 257–58,
 297, 561–62, 570–72, 650
 HIV particles 57
 HIV-related clinics 599
 HIV replication 60, 67, 70, 94, 104,
 120–21, 123, 199
 HIV risk 121, 577, 582–84, 586,
 588, 599, 633, 637, 640, 646
 HIV sero-converters 571
 HIV-susceptible cells 417–18
 HIV target cells 68, 152, 201, 223
 HIV-target cells 58, 62, 119, 442
 HIV transmission 56, 58, 60, 62,
 64, 66, 68, 70, 74, 92–93,
 118–19, 121–22, 194,
 222–23, 257
 HIV treatment 571, 573, 579,
 597–98
 HIV type 1 (HIV-1) 221, 377, 421
 HIV type 2 (HIV-2) 421
 HIVNET-008 346, 359
 HlyB 521
 HlyD 521
 Homeostatic balance 137
 Homosexual 119, 331
 Horizontal gene transfer 525
 Hormonal contraception 75, 204,
 266, 650
 Hormonal status 57, 388
 Hot-melt extrusion 233, 263, 266,
 306, 308–9
 HPTN 035 586
 HPTN-056 347
 HPTN 059 585
 HPTN-069 356
 hu-PBL-SCID mice 68
 Human immunodeficiency virus
 (HIV) 151, 416, 459, 570
 Human papillomavirus (HPV) 121,
 351, 466
 Humanized bone marrow-liver-
 thymus (BLT) mice 254
 Humanized mouse 56, 68, 227
 Humectants 203–4
 Hyaluronan (HA; see also
 hyaluronic acid) 389
 Hyaluronic acid (HA; 425 *see also*
 hyaluronan)
 Hyaluronidase 389–90, 425
 Hydrogel 234, 242, 382, 384, 391,
 433–34
 Hydrogen bond 482
 Hydrogen bonding 297, 435, 491
 Hydrolysis 96, 235, 309, 389, 467,
 488

- Hydrophilic 234–36, 239, 241–42, 245, 266, 381, 383, 425, 462, 464, 466, 468, 478, 482, 487–88
- Hydrophilic elastomers 235
- Hydrophilic gels 200, 574
- Hydrophobic 101, 103, 205, 207, 224, 233–34, 241, 266, 381, 383, 425, 466–68, 476, 478, 487–88
- Hydrophobic interaction 435
- Hydrophobic surfaces 487
- 2-Hydroxyethyl methacrylate 234
- Hydroxyethylcellulose (HEC) 66, 176, 204, 251, 305, 344, 392, 438, 537
- Hydroxypropyl methylcellulose (HPMC) 301
- Hydroxypropylcellulose (HPC) 300, 305
- Hygienic management 575
- Hyperosmolar 128, 337–38
- Hyperosmotic 159
- Hypertonic 342
- Hypotonic 438–39
- Hysterectomy 60

- ICAM-1 512, 516–17
- ICH regions 564
- IFN- γ 347
- IgA 127, 238
- IgG 127, 238
- IL-1 122–23, 136
- IL-1 receptor antagonist (IL-1RA) 123
- IL-1 receptor I 123
 - IL-1 α 121–23
- IL-1 β 121–23, 247, 392
- IL-1RA:IL-1 ratio 123
- IL-2 131
- IL-4 131
- IL-6 122–23, 127, 247, 427
- IL-8 121–23, 127, 131, 136, 247, 427
- IL-10 131, 347, 525
- IL-17A 131
- Immune cell activation 120
- Immune mediators 66, 251, 333
- Immune response 58, 68, 120
- Immune system 251, 509–11
- Immunity 119, 122, 127–29, 133, 137
- Immunohistochemical evaluation 315
- Immunosuppressive effects 127
- Immunotoxicity 119, 125, 133, 135
- In loco residence 435, 437
- In silico 152
- In situ hybridization 60, 253
- In vitro/in vivo correlation 209
- In vitro models 58–59, 75, 132–33, 135, 246
- Independent variables 153–54
- Indinavir 226
- Indocyanine green 477, 480
- Industrial-scale production 497
- Inflammasome activation 123
- Inflammation 73, 102, 121–25, 127, 135, 198, 224, 251, 347, 351–52, 393, 518, 525
- Inflammatory cascades 121, 125
- Inflammatory chemokines 475
- Inflammatory events 120, 124, 135
- Inflammatory mediators 63, 65, 93, 122–23, 128, 137
- Infrared spectroscopy 306, 491
- Injection molding 207, 228, 240, 263–64, 542, 544
- Innate immune response 58
- Insert-rings (InIVRs) 239
- Integrase 97, 199–200, 226, 255
- Integrase inhibitors 199–200, 226, 255
- 3-Integrin 132

- Intellectual property 195, 535–36, 545
- Intention-to-treat analysis 353
- Interfacial forces 435
- INTERFERin® 430
- Interferon (IFN) 131
- Interferon- γ 347
- Interferon alpha 430
- Interferon regulatory factor 124
- Interleukin (IL) 121, 247, 392, 427
- Internal structure 311
- International Conference on Harmonization (ICH) 307
- International Partnership for Microbicides (IPM) 232
- International Pharmaceutical Federation (FIP) 244
- International Rectal Microbicide Advocates 359
- International Working Group on Microbicides 125
- Intracellular adhesion molecule 1 (ICAM-1) 516
- Intracellular drug delivery 418
- Intracellular half-life 59
- Intrauterine instillation 430
- Intravaginal cleansing 592–93
- Intravaginal comfort 295
- Intravaginal distribution 296
- Intravaginal forces 161
- Intravaginal hygiene 137
- Intravaginal ring (IVR) 536, 575
- Intrinsic activity 418, 420–21, 423
- Intrinsically conducting polymers (ICPs) 383
- Introitus 175, 296, 390
- Investigational new drug (IND) 348, 554
- Ionic strength-sensitive 382
- Ionotropic gelation 423
- iPrEx 222, 353–54, 357, 360, 469
- IQP-0528 62, 72, 176, 226, 233, 301, 314, 392
- IQP-0532 226, 233–34
- Iron(II) D-gluconate 431
- Irritation 120, 128, 206, 224, 246, 251, 315, 391, 554–55, 576, 583
- Isoosmolar 128, 338–39, 343
- Junctional proteins 66
- Jurkat cells 59
- K65R mutation 71
- Karl Fisher apparatus 311
- L. casei* 512, 516
- L. casei* 393 512, 516
- L. crispatus* 130, 513
- L. gasseri* 511–12, 517
- L. gasseri* ADH 512
- L. iners* 511
- L. jensenii* 511–16, 518–20, 522, 524
- L. jensenii* 1153 512–16, 518, 520
- L. jensenii* 1153–1666 515–16
- L. jensenii* C370 protein 513
- L. plantarum* 512, 514, 516
- L. plantarum* NCIMB8826 512
- L. reuteri* RC-14 512
- LAB engineering 523
- Labeling statements 560, 564
- Labor costs 536, 545
- Lactate dehydrogenase 427
- Lactating women 119
- Lactic acid bacteria (LAB) 510
- Lactobacilli 129–31, 298, 314, 388, 473, 513, 515–20, 522
- Lactobacillus* 66, 129–30, 298–99, 389, 423, 511, 513–15, 523, 526
- Lactococcus lactis* 513, 522

- Lactoferrin 64, 387
- Lamin A/C 438
- Lamina propria 57, 94, 128, 153, 246, 333, 429, 441
- Lamivudine (3TC) 255
- Langerhans cells (LCs) 57
- Large-scale manufacture 462
- Large-scale production 95, 417
- Latex condoms 337
- Lavage 62–64, 121, 127, 243, 316, 337
- Layer-by-layer process 434
- Leakage 64, 172, 175, 183, 204, 206–7, 292, 294, 297, 299, 382, 390, 395, 429, 437
- Leakiness 102, 343
- Lectin fusion inhibitors 470
- Lens epithelium-derived growth factor (LEDGF/p75) 97
- Lentiviruses 118
- Leukocyte 122, 135
- Leukocyte infiltration 135
- Levonorgestrel (LNG) 230
- Ligands 385, 419, 422
- Lipofectamine™ 431
- Lipophilic 482
- Lipoplexes 431, 438
- Liposomes 245, 385–87, 391, 432–34, 438
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 248, 306, 492
- Liquid–liquid extraction 471
- Liquid silicone rubber (LSR) 542
- Live microbicides 510–11, 518, 526
- Llama heavy-chain antibody fragments (VHH) 239
- Local tolerance studies 555
- Long terminal repeat (LTR) 123
- Lopinavir 101, 226
- Loss modulus 489
- Loss term in the gel 172
- Loss term in the stroma 172
- Lotions 203
- Low-grade related genital adverse events 421
- Low-income countries 194
- Lower critical solution temperature (LCST) 384
- LPQTG motif 513
- Lubricants 120, 335–39, 346, 467
- Lubrication 335, 337, 467, 593–94
- Luciferase reporter cells 64
- Luteal phase 69
- Lymph nodes 58, 93, 418
- Lymphatics 58, 172
- Lymphocytes 63, 101, 197, 254, 333, 419, 517
- Lymphocytic cells 64
- Lymphoid follicles 333
- Lymphoid organs 68, 93
- Lymphoid tissues 93
- Lypopolysaccharide (LPS) 122
- Lysozyme 298, 382
- M cells 93
- M6-protein-encoding gene 520
- Macaca fascicularis 69, 255, 433
- Macaque 63, 70, 97–98, 104, 223, 232–34, 238, 245, 249–51, 253, 255–57, 316–17, 433, 460, 480–81
- Macrophage 58, 92, 121, 254, 333, 426, 475, 517
- Macrophage inflammatory protein (MIP) 121
- Macrophage inflammatory protein 1 β (MIP-1 α or CCL4) 29, 93, 123, 512, 517
- Macrophage inflammatory protein 3 α (MIP-3 α or CCL20) 58, 92, 475
- Magnetic resonance imaging (MRI) 296, 344, 419
- Male-to-female transmission 193, 201

- Mannose 422, 513
- Manufacturing changes 264, 552
- Manufacturing cost model 545
- Manufacturing costs 266, 465, 498, 535
- Manufacturing facilities 552
- Manufacturing facility 545
- Manufacturing processes 536, 551
- Manufacturing requirements 493
- Manufacturing scalability 493
- mapk1* 430
- Maraviroc (MVC) 74, 466, 474
- Marketing 309, 443, 536, 541, 550, 552, 557, 561–64, 594
- Marketing approvals 557, 562–64
- Marketing Authorization
 - Application (MAA) 561
- Mass transport theory 152, 177
- Mathematical modeling 153, 183
- Matrigel™ 60
- Matrix-assisted laser desorption ionization (MALDI) 177
- Matrix design 228, 241, 261, 541
- Matrix IVRs 228–35, 241–42, 246, 249, 258, 261, 263–64
- MDP 301 585–86, 590
- Mechanical 170, 197, 235, 249, 264, 300–1, 303–4, 308–11, 313, 315, 342, 382, 385–86, 485–87
- Mechanical requirements 486
- Mechanical testing 342, 487
- Mechanism of action 298, 301, 340–41, 422, 437, 553, 555
- Mechanistic models 156
- Medical Dictionary for Regulatory Activities (MedDRA) 351
- Medical grade silicone 240, 542
- Medication event monitoring system 580
- Medicines Control Council of South Africa 561
- Medroxyprogesterone acetate (MPA) 258
- Melittin 419
- Melt mixing 233
- Melting temperatures 468, 491
- Membrane fusion 95, 516–17, 521
- Men who have sex with men (MSM) 331, 572
- Menstrual cap 133
- Menstrual cycle 69, 129, 161, 176, 232, 249, 298–99, 316–17, 390
- Menstruation 296, 590
- Messenger RNA (mRNA) 102
- Messiness 294, 343, 390
- Metabolism 63, 99, 102, 180, 254, 511, 554
- Methacrylic acid/methyl methacrylate copolymer 424
- Methyl- β -cyclodextrin 431, 474
- Methylparaben 298, 537
- Mice 64, 66–68, 74, 100, 227, 248, 254, 337, 419, 427, 430–32, 438, 492, 515, 521–22
- Microbe-associated molecular patterns 124
- Microbial dysbiosis 135
- Microbicide development program 550
- Microbicide dosage forms 292, 459, 461, 494
- Microbicide drug delivery 91–92, 94, 96, 98, 100, 102, 104, 194, 196, 203, 459–60, 462, 464, 466, 509–10
- Microbicide formulation 98, 196–97, 206–8, 310, 341, 343, 345–46, 460, 535–36, 538, 540, 542, 544, 546
- Microbicide introduction programs 577
- Microbicide nanosystems 434, 437, 439
- Microbicide products 151, 155, 176–79, 181, 203–4, 206, 208–9, 314–17, 342, 345,

- 416–17, 429, 535, 549–51, 556–59
- Microbicide-related costs 598
- Microbicide safety 59, 65, 119, 121–23, 127, 130, 132–33, 251, 314–17, 349
- Microbicide safety algorithm 127, 130
- Microbicide trial populations 584
- Microbicide Trials Network 96, 128, 260, 468, 492, 542
- Microbicides Development Programme 585
- Microbicides Trial Network 64
- Microbiological testing 342
- Microbiota 124, 129–31, 136, 197–99, 252–53, 297–99, 301, 316–17, 509–12, 514–16, 518, 520, 522, 524, 526
- Microbiota–epithelial interactions 130, 136
- Microbubbles 386
- Microcapsules 385
- Microemulsions 201
- Microfibers 431
- Micronized API 307
- MIRA 592
- Mitogen-activated protein kinase 1 430
- MIV-150 72, 96, 126, 200, 226, 234, 245, 257, 417
- MIV-160 226, 234, 245, 257
- MK-2048 226
- Model validation 178–79
- Modified Franz diffusion cell 314
- Moisture 308–10, 395
- Molecular dispersion 462, 468, 490
- Molecular weight (MW) 462
- Monocyte 58, 254
- Monogamous couples 585, 636
- Monogamy 195
- Monolayers 122, 132, 253, 314, 384, 422, 441
- Monomers 389, 434, 475, 488
- Mononuclear cells 59, 347, 355, 389, 426, 441, 492, 514
- Mononuclear phagocytic system 519
- Morbidity 194
- Mortality 194
- mRNA 102–3, 127, 347
- MRP 99–101
- MRP1 100–1
- MRP2 101
- MRP3 100
- MRP4 100–1
- MRP5 100–1
- MT4 cells 261
- MTN-001 62–63, 356–57, 468, 588
- MTN-013 356
- Mucin 297–98, 393, 425, 428, 435–37
- Mucoadhesion 393, 418, 423, 434–35, 437, 439–40
- Mucoadhesive behavior 439–40
- Mucoadhesive film 303
- Mucoadhesiveness 206–7
- Mucosal barrier 93, 119
- Mucosal colonization 524, 526
- Mucosal disruption 335
- Mucosal drug delivery 154, 394, 435, 511
- Mucosal environment 119, 129
- Mucosal epithelium 99, 172–73, 251
- Mucosal folds 438
- Mucosal inflammation 102, 123, 125, 135, 518
- Mucosal mononuclear cells 347
- Mucosal residence 417, 442
- Mucosal responses 120
- Mucosal toxicity 125, 127
- Mucus 57, 119, 161, 295, 297–98, 388, 390, 393, 416, 434–40, 442
- Mucus-penetrating particles (MPPs) 393

- Multi-compartment IVR 260
- Multi-compartmental 247
- Multi-dose tube 575, 601
- Multi-jet nozzleless electrospinning 497
- Multi-nozzle electrospinning 495–96
- Multi-nozzle systems 462, 496
- Multiple partners 584, 586
- Multipurpose prevention 432, 474
- Multipurpose technology (MPT) 242
- Murine 64–69, 74, 131, 248, 430, 433
- Murine safety model 66
- Murine-specific CD4-siRNA 430
- Myeloperoxidase (MPO) 131

- N*-linked high-mannose glycan clusters 422
- Nanocages 384
- Nanocapsules 385
- Nanocarriers 382, 391, 418, 420, 423, 427, 429, 431–32, 434, 437, 441–42
- Nanofibers 431–32, 462, 468–70, 488
- Nanolipogels 433–34
- Nanomedicine 415, 420
- Nanoparticles (NPs) 382, 416, 469
- Nanoscale 418, 420, 435
- Nanoshells 384
- Nanospheres 385, 420
- Nanostructures 384–85
- Nanosystems 416, 418–21, 423, 425, 427–29, 431–40, 442
- Nanotechnology 203, 318, 393, 415–16, 418–20, 422, 424, 426, 428, 430, 432, 434, 436–43, 465, 483
- Nanotechnology-based microbicides 416, 418–20, 434, 437, 441–43
- Naphthalene disulfonate 421
- Naphthalene sulfonate 203
- Naphthylesterase 388
- National Institute of Allergy and Infectious Diseases (NIAID) 125, 351
- National Survey of Sexual Health and Behavior (NSSHB) 334
- Natural killer (NK) cells 68
- Nectin-1 431
- Needle-free electrospinning 462
- Neisseria gonorrhoeae* 433
- Nelfinavir 226
- Neutrophil elastase (NE) 122
- Neutrophils 121, 123
- Nevirapine 226, 243, 255
- New chemical entity (NCE) 550
- New Drug Application (NDA) 561
- Newtonian fluids 156–57, 166
- NF- κ B nuclear translocation 127
- Nissle 1917 512, 521–22
- NOD/SCID γ ^{-/-} mice 68
- Non-adherence 353–54, 357, 360, 576, 578–79, 588, 600
- Non-adherent participant 579
- Non-clade B 58
- Non-clinical development program 553
- Non-clinical toxicology 553
- Non-human primate (NHP) 92, 334
- Non-linear release 233, 241
- Non-Newtonian fluids 156, 166
- Non-nucleoside reverse transcriptase inhibitor (NNRTI) 62, 73, 202, 417, 471
- Non-polarized 60, 339
- Non-pregnant women 119
- Non-rodent 315
- Non-sink conditions 233–34, 245
- Nonoxynol-9 (N-9) 56, 120, 123, 200, 291, 336, 492, 570
- Norethindrone 230, 240, 258
- Novasome® 432

- Nozzle 461–62, 489–90, 494–97
 Nuclear factor κ B (NF- κ B) 121, 124
 Nucleoside kinases 355
 Nucleoside reverse transcriptase inhibitor (NRTI) 73, 222, 475
 Nucleotide-binding oligomerization domain (NOD)-like receptors 124
 Nucleotide reverse transcriptase inhibitor (NtRTI) 222, 468
 Nugent scores 131, 136
 NuvaRing® 231, 241–44, 252, 260
 Nylon 6 (polycaprolactam) 204
- OAT 99
 OAT1 100
 OAT3 100
 OATP 99, 101, 103
 OATPB 100
 OATPE 103
 OBP601 226
 OCT 99, 101, 251–52
 OCT2 100
 OCT3 100
 OCTN1 103
 Octylglycerol 433
 Ointment 203
 Oligomannose 422
 One-kettle process 538
 Operational costs 544
 Optical coherence tomography (OCT) 251
 Oral PrEP 58, 68, 356–57, 360, 550, 557–58, 576, 597, 600, 602–3
 Organotypic cultures 133
 Oscillation frequency 489
 Osmolality 338, 342, 350, 391
 Osmotic gradients 159
 Osmotically induced advection 438
 Over-the-counter (OTC) 120, 292, 336
- Ovine immunoglobulin G (ov-IgG) 238
 Ovulation 230, 240, 249, 258, 260
- P. bivia* 129, 131
 P-glycoprotein (P-gp) 99
 P₂₃ promoter 514, 522
 p24 60–61, 72, 339–40, 348, 358, 473, 517
 p51 polypeptide 96
 p66 polypeptide 96
 p1063 519
 Package 309–10, 537, 556–57, 559, 561
 Package inserts 556
 Packaging 306, 308–10, 539–40, 542, 544, 580
 Packets 308
 Paper applicator 539–40
 Parabens 203, 537
 Paracellular route 100
 Parallel Scientific Advice Procedure 562
 Parameter computation 178
 Parameter estimation 154, 179
 Particle delivery 469
 Particle size 393, 418
 Particles in fibers 466
 Partition coefficient 179–80, 233
 Partners PrEP 357, 469, 587
 Patent protection 545–46
 Pathogenic bacteria 252
 Pathogens 63, 124, 133, 151, 176, 181, 198, 393, 416, 418, 424, 433, 437, 440, 511
 Patient compliance 206, 293, 390
 Pattern recognition receptor 124
 Pattern structure 486
 Pectin 304, 380
 Peelability 303
 Pelvic flexure 161
 Penetration enhancer 462
 Penile glans 57

- Penile tissue 57
- Penis 346
- PEPT 99
- Peptostreptococcus* 131
- Perfluorocarbon 419
- Performance evaluation 155, 184
- Pericervical 419
- Pericoital 302, 463–64, 467–69, 482, 493
- Pericoital dosage form 468
- Peripheral blood mononuclear cell (PBMC) 301
- Peripheral lymph nodes 58
- Permeability 59, 72, 135, 170, 179, 307, 314–15, 333, 386, 388–89, 424, 427, 433, 441, 483
- Personal hygiene 196
- pH 58–59, 198, 245, 250, 298–99, 378–82, 384, 387–89, 391–92, 394–95, 424–25, 432, 439, 470–73, 490
- pH-buffering agents 74
- pH-sensitive 380, 388, 394, 424, 432, 439
- pH-sensitive polymers 439
- Phagocytic 393, 426, 519
- Pharmacodynamics (PD) 56, 152
- Pharmacokinetics (PK) 56, 152, 222, 302, 345, 396, 418, 461
- Pharmacokinetics/
 pharmacodynamics
 relationships 553
- Pharmacologic inhibitors 133
- Phase 1 61–62, 64, 95–96, 125–26, 130, 232, 260–62, 264, 347, 349–53, 355, 358, 360, 574, 576
- Phase 2 63–64, 120, 130, 261, 348, 359, 556–57, 629, 633–35, 638–40, 643, 645–49
- Phase 2/3 64, 120, 130, 261
- Phase 2b 94, 96, 128, 355
- Phase 3 96, 223, 225, 231–32, 258, 261, 263, 266, 536, 542–44, 546, 585–86, 629–33, 636–38, 640–43
- Phase-inversion process 434
- Phosphate buffered saline (PBS) 427, 462
- Phosphatidyl choline 433
- Phosphoamidase 389
- Physical appearance 307
- Physical entanglement 435
- Physical properties 72, 463, 465
- Physical stimuli 379, 384
- Physicochemical characterization 311
- Physicochemical properties 92, 98, 236–37, 241, 307, 310, 341, 417–18, 433, 462–63, 470, 475
- Pig mucosae 427
- Pig rectal mucosal tissue 441
- Pig-tailed macaque (*Macaca nemestrina*) 70
- pJRS233 517
- pKa 381
- Placebo 62, 66, 120–21, 129–31, 165–66, 201, 204, 257, 260–62, 343, 346–49, 421, 576–78, 602, 604
- Placebo gel 66, 165–66, 201, 222, 257, 302, 343, 346–49, 357, 441, 571, 576
- Plasma drug concentrations 232
- Plasma half-life 355
- Plasmacytoid dendritic cells (pDC) 93
- Plasticizers 292, 303–4, 313, 465, 491
- Platinum catalyzed silicone 541, 649
- PM1 cells 519
- pod-IVR 229, 236–38, 242–43, 248, 250, 253, 264–66
- Pods 103, 237, 242–43, 264–65, 466
- Polarized 60–61, 66, 100, 132, 314–15, 339, 342

- Poloxamer 384, 425, 428
 Poloxamer 338 425
 Poly(ϵ -caprolactone) (PCL) 393, 425, 476
 Poly(2-(4-vinylphenyl)-pyridine) (PVPPy) 381
 Poly(acrylic acid) (PAA) 379
 Poly(D,L-lactic acid) (PDLLA) 475
 Poly(D,L-lactide) (PDLA) 431
 Poly(ethylene glycol) (PEG) 204, 301, 343, 383, 438, 464
 Poly(ethylene oxide) (PEO) 385, 425, 474–75
 Poly(L-lactic acid) (PLLA) 474–75
 Poly(lactic acid) (PLA) 380, 386, 475
 Poly(ortho esters) 464, 488
 Poly(propylene glycol) 465
 Poly(propylene oxide) (PPO) 379, 425
 Poly(vinyl alcohol) (PVA) 237, 301, 305, 430, 482
 Poly(vinyl chloride) (PVC) 310
 Polycarbonate urethane 383
 Polycarophil 632
 Polychlorotrifluoroethylene (PCTFE) 310
 Polydimethylsiloxane 228, 234
 Polyesters 488
 Polyether urethane (PEU) 235
 Polyethoxylated castor oil 467
 Polyhydric alcohols 307
 Polylactide (PLA) 236
 Polylysine 421, 434
 Polymer 228, 236–39, 300–1, 303–9, 385, 391–92, 394, 423, 460–66, 468–70, 473, 475–76, 478–79, 483–85, 487–91
 Polymer blends 478, 487
 Polymer chain entanglement 461
 Polymer erosion rate 464
 Polymer melt 461
 Polymer–solvent interactions 484
 Polymeric NPs 416, 419, 436
 Polymicrobial biofilms 253
 Polymorphonuclear cells (PMNs) 135
 Polymorphonuclear leukocytes 316
 Polyplexes 430–31, 482
 Polypropylene 310, 544
 Polypurine tract (PPT) 97
 Polystyrene (PS) 420
 Polystyrene sulfonate (PSS) 300
 Polyurethane (PU) 228, 468
 Polyvinylpyrrolidone (PVP) 422, 462
 Poor solubility 417–18
 Population Council 232, 234, 240, 244, 252, 258–60, 569, 586
 Portability 293, 299
 pOsel144 512
 pOsel175 513–14, 519
 Post-coital 64, 591, 593
 Post-marketing phase 557
 Pouches 308
 Power Law model 157–59
 Praneem 585, 639
 Pre-clinical 56, 59, 65, 67–68, 74–75, 96–97, 125–26, 132–33, 135, 314, 316–17, 334, 337, 339, 552
 Pre-clinical models 56, 132–33, 135, 250, 493
 Pre-clinical safety 74, 316
 Pre-clinical vaginal product safety 120
 Pre-ejaculatory fluids 471
 Pre-exposure prophylaxis (PrEP) 56, 222, 469, 509, 550, 569
 Prefilled applicators 539, 601
 Pregnancy 57, 118–19, 221, 239, 242, 259, 296, 299, 431, 466–67, 474, 643
 Pregnant women 119, 588
 Prepare for sex 591
 Preservatives 203–4, 207, 537–38
 Prevention 118–20, 221–22, 247–48, 257–60, 291–93, 334–36, 346–48, 350–52,

- 354–60, 465–67, 556–58,
569–71, 577–79, 594–604,
629–32
- Prevention of mother-to-child
transmission (PMTCT) 597
- Prevotella* 129, 131
- Primary epithelial cell cultures
133
- Primary packaging 542, 544
- PRO 2000 58, 64, 126–27, 200,
203, 340–41, 570, 576,
643–44
- Pro-inflammatory cytokines 102,
104, 120, 123, 129, 419
- Pro-inflammatory effects 131
- Pro-inflammatory mediators 65,
122–23, 128, 137
- Pro-inflammatory response 427
- Probiotics 510
- Process documentation 552
- Prodrug 63, 235, 238, 355, 471
- Product acceptability 294, 337,
343, 348, 353, 359, 499,
562, 571
- Product approval 551
- Product design 177, 208, 294,
466, 484
- Product development 97–98, 250,
293–94, 299, 551–52, 574
- Product effectiveness 353, 570,
579, 586
- Product efficacy 298, 360, 559,
571
- Product insertion 486, 571, 575
- Product labeling 559, 564
- Product performance 176, 184,
559
- Product profile 174, 336, 552, 557,
559, 564
- Product specifications 493, 552
- Product stability 311, 466, 491
- Product use requirements 574
- Production cost 97, 265, 299
- Progesterone 161, 230, 246
- Project Gel 349, 354
- Prolonged drug release 417, 435
- Propylparaben 298, 537
- Prostatic acid phosphatase (PAP)
65
- Protease 97, 122, 199–200, 226,
243, 340–41, 483
- Protease inhibitors (PIs) 97,
199–200, 226, 340, 483
- Protein secretion 514, 521–23
- Proteolytic cleavage 96, 514, 519
- Proviral DNA 93, 333
- Proviral transcription 423
- PSC-RANTES 95, 429, 518
- pSCN112 516
- Pseudo zero-order release 229
- ptsH promoter 519, 522
- pTSV2 plasmid 514, 516
- pUC18erm vector 515
- Pullulan acetate 382
- Puncture strength 311–12
- pVDL9.3 521
- Pyrimidinedione 233–34, 245
- QPharma 263, 542
- Quadratic approximation 175
- Quality assurance/quality control
545
- Quality system regulation 551
- R5-tropic SHIV 433
- R5X4 517
- Rabbit 120, 233, 238, 248–49,
315–16, 422, 433
- Rabbit vaginal irritation (RVI) test
120, 315
- Racivir 226
- Radial squeezing flow 162
- Rag2* mice 68
- Rag2*^{-/-} γ c^{-/-} mice 68

- Raltegravir 97, 199–200, 226, 427
- Rambouillet sheep 250
- Randomized controlled trials (RCTs) 126
- RANTES analogues 104, 200
- Rapidly dissolving fibers 460
- Rat 300
- Rate-controlling membrane 229, 240–41, 245
- Rayleigh instability 461
- RC-101 60, 301, 314, 316–17
- RDEA447 226
- RDEA805 226
- Receptive anal intercourse (RAI) 332, 416
- Recombinant *Lactobacillus* 513, 526
- Recrystallization 468, 482, 491
- Rectal/colonic mucosa 57
- Rectal drug delivery 181, 480
- Rectal fluids 151, 156, 341, 480
- Rectal microbicide 128, 180, 332–33, 335–37, 339, 341, 343, 345–55, 357, 359–60, 591
- Rectal mucosa 63, 93, 119, 161, 428
- Rectal sloughing 337
- Rectal transmission 67, 416, 442, 549
- Rectosigmoid colon 345, 351, 419
- Rectum 57, 94, 161, 292, 296, 333, 341–42, 344–46, 351, 416–17, 437, 442, 463, 483, 590
- Reduced glycerin (RG) 342
- Regional lymph nodes 418
- Regulated on activation, normal T cell expressed and secreted (RANTES or CCL5) 95
- Regulatory authorities 550–52, 556–57, 559–65
- Regulatory dossier 552
- Regulatory marketing application 552
- Regulatory marketing approval 550
- Regulatory program 550
- Regulatory requirement 553
- Regulatory review and approval 550
- Regulatory strategy 493, 550–51, 565
- Regulatory submission 565
- Release profile 303, 341
- Release rate 224, 228–29, 235–37, 239, 241–43, 264, 341, 395, 463, 478
- Repeated low-dose (RLD) challenge model 256
- Reproductive toxicology 119, 554
- Reproductive tract 102, 176, 209, 392, 461, 463, 468, 475, 480
- Repulsive forces 435
- Reservoir design 228–29, 235–36
- Reservoir IVRs 229, 232, 235, 260–61, 263
- Residence time 206, 303, 459, 492
- Residual solvent 308
- Resistance 71, 91, 97–99, 202, 206, 225, 227, 465, 471, 515, 522–23, 525, 553, 557, 598
- Resistance monitoring 557
- Resistant strains 98, 227, 465, 598
- Resistant viral strains 227
- Resistant virus 104, 227, 266
- Retinoic acid-inducible gene 1 (RIG)-like receptors (RLR) 124
- Retrocyclin analogue 60, 301
- Retrocyclin entry inhibitor 226
- Reusable applicators 575
- Reverse transcriptase (RT) 69, 92, 223, 475
- Reverse transcriptase inhibitors (RTIs) 56, 91, 200
- Reverse transcription 67, 102, 127, 199, 201, 256, 352, 423, 427
- Reverse transcription polymerase chain reaction (RT-PCR) 102, 127, 256

- Revertant strain 525
- RG TFV 1% gel 342
- Rheological 119, 154–57, 159, 162–65, 167, 179, 181, 307, 309, 394, 483, 485, 488–89
- Rheometric measurements 164
- Rhesus macaque (*Macaca mulatta*) 232, 520
- Rilpivirine 62, 226
- Ring Study, The 96, 104, 261, 542
- Rings 103, 221–22, 224, 226, 228, 230, 232, 234, 236, 238–40, 242, 260–64, 395, 542, 544
- Risk of HIV infection 473, 571, 575, 583, 588, 597
- Risk ratio (RR) 128
- Risk reduction counseling 580
- Ritonavir 226, 466
- RMP-01 348
- RMP-02/MTN-006 61, 348, 355, 358
- RNase H 96–97, 226
- RNase H inhibitors 226
- Rodents 67, 249, 315
- rpsU gene promoter 515
- RT-SHIV 72, 233–34, 255, 257
- RT-SHIV-162P3 233, 255, 257
- Rugae* 160–61, 181, 296, 438
- S-DABO 200
- S. gordonii* GP1295 512
- Safe sex practices 558
- Safety 65–67, 74–75, 117–28, 130, 132–37, 247, 249–53, 260–62, 313–17, 346–53, 524–26, 552–59, 574–76, 584–85, 635–36
- Safety assessment 120, 252–53, 317, 360
- Safety biomarkers 348, 351
- Safety pharmacology 554
- Safety profile 251, 260, 553
- Safety trials 120–21, 126, 136, 260, 576, 584–85
- Sandwich reservoir IVRs 229
- Saquinavir 97, 101, 200, 226, 243, 341
- SAVVY® (C31G) 56
- Scaffolds 438, 464–65
- Scale-up 223, 264–66, 306–7, 309, 442, 494, 496–98, 535–36, 541, 544, 546
- Scanning electron microscopy (SEM) 311, 476
- scFv 512, 516–17
- SCID-hu-thy/liv mice 68
- Scientific Advice Procedure 562
- Scoring Function 174–75, 183
- Secondary packaging 539–40
- Secondary transmission 194
- Secretory leukocyte protease inhibitor (SLPI) 122
- Segmented TFV-dapivirine IVR 266
- Self-administered 292, 570
- Self-report 354, 571, 650
- Semen 59, 63–65, 73–75, 120–21, 151–54, 168–70, 199, 298–99, 344–45, 388–89, 392, 394–95, 419, 424–25, 470–73
- Semen-dependent release 471
- Semen-derived enhancer of virus infection (SEVI) 65, 392
- Semen-responsive 470–72
- Semen simulant 419
- Semen surrogate 344–45
- Semen-triggered pH changes 392
- Semenogelin I (SG-1) 64
- Semi-solid 153, 341, 391, 537
- Semicrystalline 475–76, 490
- Seminal fluid 245, 387–89, 471
- Seminal plasma 56, 58–59, 61, 63–65, 72, 74, 472, 480
- Seminal proteins 64
- Severe combined immune deficiency (SCID) 68

- Sexual abstinence 118, 589–90
- Sexual behavior 334, 580, 589–90
- Sexual expectations 593–94
- Sexual frequency 589–91, 602
- Sexual intercourse 72–73, 128, 194, 196, 201, 208, 297, 299, 317, 389, 437, 467, 511, 585, 591
- Sexual lubricants 335, 337, 339
- Sexual pleasure 335, 585, 589, 593–94
- Sexual practices 562, 574
- Sexual relationship 574, 584
- Sexual relationship patterning 574
- Sexual taboos 589–90
- Sexual transmission 56–57, 63, 74, 194, 292–93, 297, 302, 310, 511, 519
- Sexually active women 64, 126, 294
- Sexually transmitted diseases (STDs) 120, 194, 198, 231, 332
- Sexually transmitted infection (STI) 194, 463
- Sexually transmitted pathogens 151, 176, 433
- Shear rate 157–59
- Shear thinning behavior 156
- Shear thinning exponent 159
- Sheath solution 462
- Sheep 238, 242–43, 249–52, 317, 460, 554
- Shelf-life 309
- SHIV 69–72, 93–95, 97–98, 135, 232–34, 255–57, 417, 429, 433, 460, 492, 517, 526
- SHIV-SF162P 255
- SHIV_{SF162} 518
- SHIV_{SF162P3} 516, 520
- Short message service (SMS) 354
- Shuttle vectors 522–23
- Sialic acid 390, 428
- Side effects 124, 258, 293, 336, 347, 392, 462–63, 465, 482, 555, 558, 571, 574, 576–77, 597–98
- Silastic silicone 260
- SILCS diaphragm 204–5
- Silicone 103, 204, 224, 228, 230–37, 239–41, 246, 253–54, 257–60, 263, 304, 337–38, 541–43, 649
- Silicone oil 240, 542
- Silicone reservoir-IVRs 230, 246
- Silver NPs 422–23
- Simian-human immunodeficiency virus (SHIV) 93, 232, 417, 460
- Simian immunodeficiency virus (SIV) 65, 92, 135, 460
- Simple columnar epithelium 57
- Simulated semen fluid 424
- Simulated vaginal fluid (SVF) 472
- Single-chain monoclonal antibody variable fragment (scFv) 516
- Single-dose applicator 598
- Single-dose plastic applicator 537
- Single founder viruses 118
- Single or multiple dose packaging 306
- Single photon emission computed tomography (SPECT) 344
- Single photon emission computed tomography with computed tomography (SPECT/CT) 419
- Single pouch 309
- Single-use applicators 575
- Sink conditions 232–34, 245–46, 311, 482
- siRNA-based microbicides 430
- Site level 579
- SIVmac 69, 255
- SIVsm 69
- Slow dissolving 167
- Small interfering RNA (siRNA) 385, 430
- Small-scale production 308
- Social norms 574, 580

- Socio-cultural 570, 572, 574, 589, 591–95
- Sodium carboxymethyl cellulose 248, 305
- Sodium dodecyl sulfate 300, 462
- Sodium fluorescein 425
- Sodium laurylsulfate 425
- Sodium methacrylate 234
- Softness 303
- Solid dispersions 468, 483, 491
- Solid dosage forms 244–45, 291, 293, 317, 341, 416, 466, 483
- Solid lipid nanoparticles (SLNs) 434
- Solid-liquid interface 488
- Solid matrix 468
- Solid-state materials 491
- Solubility 103, 234–35, 237, 242, 245–46, 304, 307, 417–18, 424, 433, 462, 466, 468, 471–72, 482
- Soluble Film Drug Delivery Pouch 309
- Soluble intercellular cell adhesion molecule-1 136
- Soluble vascular cell adhesion molecule-1 136
- Solute carrier (SLC) transporters 99
- Solutions 158, 201, 307, 341, 389, 391, 442, 460–63, 466, 468, 475–76, 484, 490
- Solutol® (apolyglycol ester of 12-hydroxystearic acid) 245
- Solvent 233, 245, 266, 300–1, 304–8, 311, 381–82, 424–25, 430, 461–62, 468, 476, 484–85, 488, 490
- Solvent casting 233, 266, 304–8
- Solvent evaporation method 300, 430
- Sorbic acid 203–4
- South African Medicines Control Council (MCC) 587
- Spatio-temporal 168, 177, 179
- Sperm 198, 234, 386, 388–90, 472, 474–75
- Spermatozooids 419, 432
- Spermicide 120, 231, 299, 570, 582
- Spermidine 430–31
- Spherulite formation 485
- Spinnerets 495–96
- SPL7013 dendrimer 416
- Splenic flexure 344, 351, 419
- Sponge 582, 629, 631, 650
- Sponsor 348, 552, 560–61, 581
- Spreadability 206, 303
- Squeezing forces 160, 162–64, 167
- Stability 204, 206–8, 263, 266, 298, 301, 307, 309, 311, 342, 347, 384, 491, 493, 544–45
- Stabilizers 303, 434
- Stampidine 226
- Standard methods 244, 264, 483
- Static electricity 485
- Statistical significance 557
- Steady partners 583, 587
- Steady-state drug levels 250
- Steric hindrance 435
- Stimulator of interferon genes 124
- Stimuli-sensitive 377–80, 382, 384, 386, 388, 390, 392, 394–96, 425, 442
- Storage 205–6, 229, 240, 299, 306, 425, 482, 489, 493, 575
- Storage modulus 489
- Storage temperature 425
- Stratified squamous epithelium 57, 296, 317
- Stromal tissue 60
- Structural conformation 378
- Structural integrity 476, 484, 486
- Structural properties 462, 491
- Sub-diffusive transport 393, 425
- Sub-epithelial 119
- Sub-Saharan Africa 137, 194–95, 331, 334, 359, 539, 542, 549, 561–62, 584

- Subliming solid matrices 204
- Submucosa 57, 120
- Submucosal tissues 223
- Succinic dehydrogenase 389
- Sulfate-ended ligands 422
- Sulfonate-91 terminated
 - carbosilane dendrimer 422
- Sulfur colloid particles 345
- Superhydrophobic materials 487
- Superparamagnetic iron oxide NPs (SPIONs) 386
- Supersaturated concentrations 460
- Suppository 153, 343–44, 582, 631
- Surface-area-to-volume ratio 418, 463, 467, 469
- Surface chemistry 435, 440, 487–88
- Surface erosion 467, 479, 488
- Surface modifiers 425, 439
- Surface plasmon resonance 422
- Surface properties 435–36, 462, 485
- Surface tension 160, 166, 181, 461, 484, 487
- Surfactants 74, 94, 126, 200, 300, 482, 487, 492
- Suspensions 341
- Sustained drug delivery 67, 201, 224, 228
- Sustained drug release 202, 417, 462, 464, 479, 488
- Swelling 159, 164–65, 181, 235, 241, 311, 313, 393, 466, 487–88
- Swelling index 311, 313
- Synergism 418
- Synergistic activity 71, 98
- Synergistic effects 227
- Systemic absorption 207, 262, 559, 575–76
- Systemic drug exposure 206, 248, 437
- Systemic effects 341
- Systemic safety 559
- T cells 57–58, 60–61, 64–65, 67–68, 72–73, 92–94, 99–100, 102, 123, 137, 152, 223, 297, 422, 429
- T lymphoblastoid cell line (CEM-SS) 301
- T45 512
- T1249 341, 512, 516–17
- Tableting 264–65
- Tablets 56, 126, 182, 201, 203, 207, 239, 244, 291, 294, 459, 464, 466, 468, 471
- Tampon-shaped molds 431
- Tampons 296
- Target cell 62, 199, 483, 551, 557
- Target countries 550, 562–63
- Target population 555, 564
- Target product profile (TPP) 559
- Target-specific 378
- Targeted drug delivery 435
- Taylor cone 461, 484, 497
- TDF2 469
- Technetium-99m (^{99m}Tc)-sulfur 419
- Tenofovir 56, 91, 126, 172–73, 222, 226, 302, 340–41, 348, 358, 466, 470, 536–37, 539, 646–50
- Tenofovir disoproxil fumarate (TDF) 222
- Tensile strength 303, 308, 311–13, 486
- Tensile testing 486
- Terameprocol 203
- Terpolymers 464
- Testing algorithms 342
- Texture 307, 311, 313, 353, 388, 467, 485
- TFV 1% gel 61, 94, 126, 128, 342, 348–50, 355–56,

- 536–39, 541, 571, 575–76, 585
- TFV diphosphate (TFV-DP) 235, 349, 358
- TFV film 302
- Therapeutic index 65, 338
- Thermo-responsive 384
- Thermodynamic barrier 463, 468
- Thickening agents 304, 307
- Thickness 161, 168–70, 172, 177, 180, 230, 237, 251–53, 295, 297, 307–8, 311–12, 381, 574
- Thickness of epithelial layers 295
- thyA* gene 525
- Tibotec Pharmaceuticals 231
- Tight junctions 93, 102, 104, 333, 424
- Time-dependent deployment 153
- Tipranavir 226
- Tissue accumulation 393, 441
- Tissue concentrations 232, 234, 243, 246, 357, 437
- Tissue culture models 56
- Tissue damage-associated molecular patterns 124
- Tissue distribution 92, 102
- Tissue explants 62, 133, 342, 460, 481, 553
- Tissue levels 102–3, 238, 243, 355–56, 469
- Tissue penetration 59, 63, 468
- Tissue retention 418
- Titanium dioxide 240, 304
- TLR-mediated cytokine expression 127
- Toll-like receptor 124
- Tomography 251, 344–45, 419, 487
- Tonicity 438
- Topical drug delivery 126, 154
- Topical formulations 56
- Topical PrEP 58–59, 66, 70–71, 223, 225, 227, 266
- Total elongation to fracture 486
- Toxicity 125, 127, 197, 204–5, 249, 315, 342, 417–18, 427, 433, 441–42, 473, 480, 491–92, 554–55
- Toxicokinetics 553–54
- Toxicological assessment 119
- Toxicological profile 555
- Transactional sex 584, 586
- Transcutaneous electrical nerve stimulation (TENS) 391
- Transcytosis 93, 333, 387
- Transepithelial electrical resistance (TEER) 59, 246
- Transfection agent 430
- Transfer coefficients 154
- Transformation zone 57, 297
- Transgenic GFP mouse model 431
- Transgenic rats 67
- Transmission risk 123
- Transport process 153
- Transport theory 152, 156, 177, 483
- Transvaginal flow 161
- Transverse folds 161
- Transwell® system 66, 339
- Trial endpoints 558
- Trial-specific factors 578
- Trichomonas vaginalis* 122, 252
- TRIM5 α 69
- Tripartite interaction motif 124
- Trovirdine hydrochloride 255
- Truvada® 70, 222, 225, 302, 353–54, 550, 558, 649–50
- TSAO-m³T 255
- Tube-filling 539
- Tubes 228, 241, 265, 468, 537, 539–41
- Tumor necrosis factor (TNF) 123, 419
- Tunable polymer design 462
- Two-kettle process 537, 540
- Type 4 dissolution apparatus 492

- Tyrosine-derived polycarbonate 464
 TZM-bl cell 338, 427, 429, 434
- UC-42 255
 UDP-glucuronosyltransferase (UGT) 102
 Ulcerations 120
 Ultimate tensile strength 486
 Ultra-violet (UV) 378
 United States Agency for International Development (USAID) 125
 United States Pharmacopeia (USP) 244
 Universal placebo 165–66, 204, 421
 Unprotected sex 118, 464, 471, 631
 Urovagina 249
 US National Institutes of Health (NIH) 349
 Use-effectiveness 293
 Used applicator count 571
 User-filled 537, 539–41
 User sensory perceptions 183
 Usher cell 126, 203
 Uterine horns 419, 431
 Uterus 296, 419
- V3 58
 Vaccine 56, 118, 195, 420, 509, 511
 Vaccine adjuvants 420
 Vagina 159–61, 175–76, 196–200, 203–4, 249–50, 292, 295–99, 314, 316–17, 387–91, 416–19, 437–38, 480, 482–83, 592–94
 Vaginal 65–69, 93–98, 118–22, 125–33, 151–68, 170–74, 179–84, 231–39, 248–62, 291–318, 387–96, 426–34, 511–21, 589–94, 633–43
 Vaginal and Oral Interventions to Control the Epidemic 128, 302
 Vaginal applicators 539
 Vaginal bacteria 129, 132, 483
 Vaginal biopsies 177, 355
 Vaginal canal 153–54, 156, 160, 170–72, 181, 423
 Vaginal discharge 297
 Vaginal drug delivery 236, 248, 295–98, 459, 469, 474, 493, 499
 Vaginal environment 129, 135, 203, 293, 299, 313, 429
 Vaginal epithelial cells 121–22, 130, 132, 245, 423, 434, 473, 516
 Vaginal epithelium 59, 69, 93, 153, 168, 170, 172, 197, 223, 246, 249, 388, 432, 517, 519
 Vaginal explants 433
 Vaginal films 166, 203, 291–93, 295, 299–301, 303, 306–7, 309–11, 314, 317, 395, 467, 489, 494
 Vaginal fluid 153–54, 159, 162, 170, 172, 179, 182, 232–39, 292, 294–95, 297–98, 388, 393–94, 472–73, 476
 Vaginal Fluid Simulant (VFS) 298
 Vaginal gels 56, 127, 164, 183, 203, 294, 392, 459, 645
 Vaginal hygiene practices 592
 Vaginal intercourse 419, 582
 Vaginal irritation studies 315
 Vaginal leakage 467
 Vaginal microbicides 100–1, 125, 206, 208, 252, 258, 314, 417, 570, 589, 592, 598

- Vaginal microbiome 66–67, 75, 224, 246, 251–54, 259
- Vaginal microbiota 66, 75, 129–31, 197, 229, 298–99, 301, 316, 511, 515
- Vaginal mucosa 128, 223, 258, 292, 303, 378, 390, 511, 515, 520–21
- Vaginal pH 65, 198, 208, 225, 250, 298–99, 317, 388, 439, 470, 473, 511
- Vaginal practices 129, 589, 591–92
- Vaginal ring 96, 236, 260, 356, 541–44, 550, 554, 649
- Vaginal rugae 161, 296
- Vaginal Scented Film 292, 299
- Vaginal surface area 174, 183
- Vaginal tissues 136, 235, 248, 356
- Vaginal wall 164, 297, 388, 390–91, 574
- Vaginitis 120
- Vaginosis 122, 197, 298, 473
- Vascular congestion 135
- VCF® Vaginal Contraceptive Film 292, 299
- Viral capsid 69
- Viral diffusion 119
- Viral dissemination 93
- Viral DNA synthesis 63
- Viral dynamics 152, 180
- Viral entry 64, 67, 94, 120, 225, 301, 316, 512–14, 518, 521
- Viral load 57, 347, 357
- Viral protein U inhibitors 226
- Viral replication 93, 104, 152, 340, 358
- Viral resistance 206, 465, 553
- Viral RNA 57, 199, 333
- Viral shedding 123
- Viral strains 57, 227, 553
- Virion neutralization 168
- Virions 119, 135, 151–52, 156, 168–70, 199, 420, 433, 499, 521
- Virucidal 120, 198
- Virucidal activity 120
- Virucides 198
- Viscoelastic 390
- Viscoelasticity 390, 489
- Viscosity 154, 157–59, 179, 206, 295, 304, 342, 344, 389–90, 393, 461, 484, 489
- VivaGel® 126, 416, 420–21, 441–42
- VK2/E6E7 cells 122, 432
- Volume of gel 343, 539
- VRC01 227
- Water-based lubricants 337, 339
- Water content 311
- Wettability 303, 487
- WHO Prequalification 563
- Wide-angle X-ray diffraction 490
- Willingness to use products 571
- WisePill dispenser 580
- World Health Organization (WHO) 125, 230, 550
- X-ray diffraction (XRD) 306
- X-ray spectroscopy 479
- Yield strength 486
- Yield stress 154, 156–57, 159, 165
- Young's modulus 311–13
- Zero-order kinetics 233
- Zero-order release 170, 229, 237, 464
- Zero-shear rate viscosity 159
- Zidovudine (AZT) 234, 470, 474
- Zinc acetate 72
- Zinc finger nuclease 226